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ABSTRACT 
 
Characterization of Chronic Enteropathies in Dogs by Use of Fecal and Urinary  
N-methylhistamine Concentrations and Serum Methylmalonic Acid Concentrations. 
(August 2012) 
Nora Berghoff, med.vet.; Dr.med.vet., University of Veterinary Medicine, Hannover, 
Germany 
Chair of Advisory Committee: Dr. Jörg M. Steiner 
 
Non-invasive markers that are clinically useful for the diagnosis and monitoring 
of canine chronic enteropathies are scarce. The first aim of this study was to investigate 
the prevalence of cobalamin deficiency on a cellular level in dogs with chronic 
gastrointestinal disease by measuring serum methylmalonic acid (MMA) concentrations. 
Hypocobalaminemia has been associated with a negative outcome in dogs with chronic 
enteropathies, but the prevalence of cellular cobalamin deficiency is unknown. The 
second aim of this study was to determine the utility of fecal and urinary concentrations 
of N-methylhistamine (NMH) as a marker of gastrointestinal inflammation and disease 
activity in dogs with chronic enteropathies.  
Serum MMA concentrations were measured in healthy control dogs to establish a 
reference interval, which was calculated to be 415-1,193 nmol/L. Measurement of MMA 
concentrations in 555 serum samples from dogs with varying cobalamin concentrations 
showed a significant increase (p<0.05) in dogs with hypocobalaminemia. In a 
prospective group of 56 dogs with chronic enteropathies, 36% had decreased serum 
cobalamin concentrations, five of which (9% of 56 dogs) had increased serum MMA 
concentrations. We conclude that hypocobalaminemia is commonly seen in dogs with 
chronic gastrointestinal disease, but does not always appear to be associated with cellular 
cobalamin deficiency.  
In 47 dogs with chronic enteropathies, fecal and urinary NMH concentrations 
were increased in 21% and 27%, respectively, indicating that mast cell degranulation 
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plays a role in a subset of dogs with chronic enteropathies. However fecal and urinary 
NMH concentrations did not correlate with each other, or with the clinical activity index. 
Urinary NMH concentrations correlated significantly with serum CRP concentrations, 
and were also significantly associated with severity of duodenal mucosal inflammation 
(p=0.008). The lack of correlation with the clinical activity index suggests that 
degranulation of mast cells only plays a role in some dogs with chronic enteropathies. 
Also, these results suggest that NMH alone may not be a good marker for clinical 
disease activity in dogs with chronic enteropathies. Due to its linear association with 
serum CRP and severity of mucosal inflammation, urinary NMH concentrations may be 
a better marker of intestinal inflammation than fecal NMH concentrations. 
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NOMENCLATURE 
 
ALP   Alkaline phosphatase 
1-PI  Alpha1-proteinase inhibitor 
ALT   Alanine aminotransferase 
ARD   Antibiotic-responsive diarrhea 
AST   Aspartate aminotransferase 
CCECAI  Canine chronic enteropathy clinical activity index 
CRP C-reactive protein 
cTLI    Canine trypsin-like immunoreactivity 
d3-MMA  Trideuterated methylmalonic acid 
d3-NMH  Trideuterated N-methylhistamine 
ELISA   Enzyme-linked immunosorbent assay 
EPI   Exocrine pancreatic insufficiency 
FRD   Food-responsive diarrhea 
GC/MS  Gas chromatography/mass spectrometry 
GGT   Gamma-glutamyltransferase 
HNMT Histamine N-methyltransferase 
IBD Idiopathic inflammatory bowel disease  
MMA   Methylmalonic acid 
MSD   Mass selective detector (mass spectrometer) 
MTBSTFA  N-methyl-N- (tert-butyldimethylsilyl)-trifluoroacetamide 
m/z   Mass-to-charge ratio 
NMH N-methylhistamine 
PFPA  Pentafluoropropionic anhydride  
PLE Protein-losing enteropathy 
RIA Radioimmunoassay 
rs Spearman’s rank correlation coefficient 
Spec cPL® Serum canine pancreas-specific lipase 
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1. INTRODUCTION 
  
1.1 CANINE CHRONIC ENTEROPATHIES  
 Chronic enteropathy is a term used for diseases of the intestines regardless of 
etiology and pathogenesis. Chronic enteropathies are commonly seen in the dog. 
Objective laboratory tests that are clinically useful for the diagnosis and monitoring of 
canine chronic enteropathies are scarce. Specifically, non-invasive markers for 
gastrointestinal inflammation in the dog that have been shown to be clinically useful are 
currently not widely available. Likewise, tests that may help distinguish the different 
forms of chronic enteropathies are lacking, making it nearly impossible to predict a 
response to treatment in affected dogs.1,2  
Differentiating the various types of canine chronic enteropathies is complicated 
due to a current lack of uniformity among authors in defining these entities. Particularly, 
the term “inflammatory bowel disease” is not well defined in veterinary medicine. 
Technically, inflammatory bowel disease describes any condition associated with an 
inflammatory infiltration of the GI tract.3 Idiopathic inflammatory bowel disease (IBD), 
however, is any condition associated with presence of chronic (>3 weeks) 
gastrointestinal signs and an inflammatory infiltration of the GI tract where a specific 
etiology cannot be identified. Thus, a distinction should be made between idiopathic 
IBD, in which the cause is unknown, and those types of gastrointestinal inflammation for 
which an underlying cause can be determined.3  
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Frequently, the response to treatment is used to allow for distinction of different 
types of enteropathies, such as food-responsive diarrhea (FRD), antibiotic-responsive 
diarrhea (ARD), and steroid-responsive diarrhea (SRD),2 all of which can be features of 
idiopathic IBD. Treatments are applied in a sequential fashion, starting with a dietary 
trial, followed by antibiotic therapy if there is a lack of response to diet, and finally, 
treatment with anti-inflammatory drugs, if response to previous treatments was 
inadequate.2   
The reason for a response to these therapeutic approaches, or lack thereof, in 
dogs with idiopathic IBD is currently unknown.4 Many patients with chronic 
enteropathies that respond to a change in diet can later be switched back to their original 
diet.1 This would not be possible if a true adverse food reaction, such as food allergy or 
food intolerance, was the cause of the enteropathy.5 Instead, it has been suggested that 
improved nutrient bioavailability resulting from an intestinal or elimination diet, or 
additives such as fructooligosaccharides and/or higher n3-n6 fatty acid ratios may be 
partially responsible for the favorable response to a change in diet in these dogs.5  
Thus, diagnosis of canine chronic enteropathy and idiopathic IBD currently 
remains a diagnosis of exclusion (i.e., ruling out other causes of intestinal disease and 
inflammation). This situation highlights the need for laboratory tests that would help 
differentiate different types of chronic enteropathies.  
Pathogenesis of idiopathic IBD is generally believed to be multifactorial.2 A 
currently accepted hypothesis in humans, dogs, and cats is that of a dysregulation of the 
gastrointestinal immune system in genetically susceptible individuals, which may lead to 
aberrant responses towards luminal microbial or dietary antigens.6-9 Inappropriate 
immune regulation may cause loss of tolerance of commensal bacteria, and possibly 
other antigens (e.g., dietary components).2,9 This multifactorial pathogenetic theory 
suggests that different avenues should be explored so that laboratory tests with clinical 
utility can be discovered.  
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1.2 PREVIOUSLY INVESTIGATED MARKERS OF DISEASE FOR DOGS 
WITH CHRONIC ENTEROPATHIES 
Several molecules that may play a role in the pathogenesis of IBD have been 
investigated as potential disease markers in dogs with chronic enteropathies. These 
include toll-like receptors, cytokines, and markers of inflammation:   
  Toll-like receptors - Toll-like receptors (TLR) are important in intestinal 
immune regulation. They recognize microbe-associated molecular patterns (MAMPs) 
present on microbial organisms. Toll-like receptors are expressed by a variety of cell 
types including epithelial cells as well as cells of the innate immune system (e.g., 
macrophages, dendritic cells, mast cells).10,11 In humans, mutations of TLRs have been 
found to be associated with IBD, suggesting that they play a role in regulating mucosal 
homeostasis.12 The TLRs studied in dogs to date are TLR2, TLR4, TLR5, and TLR9, 
which recognize lipoproteins, lipopolysaccharide, flagellin, and unmethylated bacterial 
or viral CpG DNA, respectively.11 Binding of the respective ligand to its TLR causes 
translocation of the transcription factor Nuclear Factor-κB (NF-κB) into the nucleus, 
which subsequently initiates transcription of genes encoding pro-inflammatory 
cytokines, such as TNF-α, IL-1ß, and IL-6.11   
One study in dogs evaluated mRNA expression of canine TLR2, TLR4, and 
TLR9, and found all three TLRs to be upregulated in dogs with chronic enteropathies.13 
Interestingly, expression profiles did not change after dogs were treated and had 
improved clinically, supporting the hypothesis of a genetic predisposition that caused an 
aberrant immune response. Another study found increased TLR2 expression in dogs 
with idiopathic IBD, but TLR4 expression was not different from controls.14 A third 
investigation found increased expression of TLR4 in German Shepherd dogs (GSD) with 
chronic enteropathies, whereas TLR5 was decreased and TLR2 and TLR9 were 
unchanged.8 Furthermore, a risk-associated haplotype of TLR5 has recently been 
identified in German Shepherd dogs and has been shown to be significantly hyper-
responsive to flagellin.15 The authors hypothesized that this may be partially responsible 
for the exaggerated inflammatory response seen in dogs with idiopathic IBD.15 
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These reports demonstrate that an aberrant expression of TLRs in dogs with 
chronic enteropathies occurs and warrants further investigation to understand the exact 
pathogenetic mechanisms of the disease. However, due to discrepant results between the 
different studies, no single TLR or combination of TLRs can currently be recommended 
as a diagnostic marker for dogs with chronic enteropathies. Also, the need for intestinal 
biopsies limits the clinical utility of these tests as a diagnostic aid.  
Cytokines  - Mucosal mRNA expression of inflammatory cytokines as an 
indirect measure of the intestinal immune response is another area of investigation. In 
humans, various cytokines have been associated with IBD.6 More specifically, TNF-α 
and IL-12p40 have been implicated in the pathogenesis of Crohn’s disease in humans. 
Several studies have been carried out in dogs, investigating a variety of cytokines.16-18  
A study by Peters et al. looked at mRNA expression of IL-2, IL-4, IL-5, IL-6, IL-
10, IL-12, IL-18, IFN-γ, TNF-α, and TGF-ß in dogs with chronic enteropathies and 
healthy control dogs. Investigators were unable to find significant differences in 
cytokine mRNA expression between the two groups of dogs.16 Another investigation 
showed that dogs with lymphocytic-plasmacytic colitis had a higher expression of IL-2 
and TNF-α.17 However, the opposite was shown in a study by Jergens et al.18 In this 
report, a meta-analysis of four studies was performed, and the authors concluded that 
only IL-12 was consistently overexpressed in dogs with idiopathic small intestinal 
IBD.18 
Overall, there is a lack of an obvious pattern of cytokines that are differentially 
expressed in dogs with chronic enteropathies. This may in part be due to differences in 
methodology, sampling populations, and types or stages of disease between the studies. 
There is some evidence that IL-12 may be overexpressed in dogs with chronic 
enteropathies, which would mirror reports in human patients with IBD.6,18  
The ability to measure cytokine concentrations in serum or plasma samples 
would be more clinically relevant than determination of mRNA expression profiles in 
intestinal biopsies, as it would be less invasive and results could be obtained more easily 
and less invasively. Unfortunately, studies determining the clinical utility of cytokines as 
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a marker of disease in dogs with IBD are lacking. One study evaluated use of a serum 
TNF-α assay in dogs with IBD, but TNF-α concentrations were not different in dogs 
with IBD compared to the reference population.19 Thus, further investigations are 
required to determine which cytokines play a role in the pathogenesis of canine 
idiopathic IBD, and if any cytokines may be clinically useful, especially when measured 
in serum or plasma.   
Inflammatory markers - pANCA and C-reactive protein have been investigated 
as markers of inflammation in dogs with chronic enteropathies. 
pANCA - Perinuclear antineutrophilic cytoplasmic antibodies (pANCA) are used 
as a marker of inflammation in human patients with IBD to distinguish patients with 
ulcerative colitis from those with Crohn’s Disease. pANCAs are autoantibodies that 
produce a characteristic perinuclear staining pattern in granulocytes when stained with 
immunofluorescence detection methods.20 In human patients with IBD, pANCAs can be 
identified in the serum of about 50% to 80% of patients with ulcerative colitis, whereas 
most patients (70%–90%) with Crohn’s disease are negative.20,21  
In dogs, an assay for the detection of pANCA had a variable sensitivity from 
23% to 51% and a specificity of 83% to 95% for canine IBD.20-22 Thus, there appears to 
be an association between the detection of pANCA and IBD in dogs, but because of its 
poor sensitivity, the assay may not be useful as a screening test for IBD.20 Interestingly, 
one study found a higher rate of pANCA positive samples from dogs with FRD (62%) 
when compared with those from dogs with idiopathic IBD (23%).21 Furthermore, 20 of 
21 Soft-Coated Wheaten Terriers with protein-losing enteropathy and nephropathy (PLE 
and PLN, respectively) were positive for pANCA.23 In most of these dogs, pANCA was 
positive one to two years before onset of hypoalbuminemia, and the assay was able to 
predict PLE and/or PLN with a sensitivity of 95% and specificity of 80%. Thus, this test 
may prove helpful in early diagnosis and, once preventative strategies have been 
identified, in early treatment of affected dogs.23   
C-reactive Protein - C-reactive Protein (CRP) is a positive acute phase protein, 
meaning that its serum concentration increases in response to an inflammatory stimulus, 
  
6
regardless of the affected organ. While this response is not specific to the intestinal tract 
and can be caused by inflammatory conditions throughout the body, one study has 
shown significantly increased serum CRP concentrations in dogs with moderate to 
severe IBD, when compared to a group of healthy control dogs.24 Another investigation 
demonstrated that serum CRP concentrations in dogs with IBD decrease significantly 
after treatment.25 However, other investigators were not able to detect a difference in 
serum CRP concentrations between healthy dogs and dogs with IBD.1,19  
Therefore, while measurement of serum CRP concentrations is of limited use in 
diagnosis of canine IBD and assessment of clinical disease activity, it may be beneficial 
in evaluating response to treatment in individual patients.   
 
 
1.3 NEW MARKERS WITH POTENTIAL TO AID IN THE DIAGNOSIS AND 
MONITORING OF CANINE CHRONIC ENTEROPATHIES  
Based on the results obtained from the aforementioned studies, it is clear that 
clinically useful markers for diagnosis and monitoring of canine chronic enteropathies 
are still lacking. Ideally, a test should be non- or minimally invasive and thus should be 
using blood, urine, or fecal samples, as opposed to intestinal biopsies. A test should also 
be quick and convenient to use, providing a fast turnaround time. The following 
describes two new markers with potential usefulness for the diagnosis and monitoring of 
canine chronic enteropathies.  
Serum methylmalonic acid concentration as a marker of cobalamin 
deficiency on a cellular level in dogs - Cobalamin (vitamin B12) is a water soluble 
vitamin that requires a complex set of physiologic mechanisms for intestinal 
absorption.26,27 Protein-bound cobalamin is released after partial digestion of the protein 
in the stomach, but immediately binds to haptocorrin (aka R-protein or cobalophilin). In 
the small intestine, a higher pH and action of pancreatic proteases result in dissociation 
of haptocorrin from cobalamin, and free cobalamin binds to intrinsic factor. The 
cobalamin-intrinsic factor complex is then absorbed by receptors on ileal enterocytes.  
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In dogs, cobalamin deficiency usually develops in patients with exocrine 
pancreatic insufficiency or distal small intestinal disease, or may be caused by genetic 
defects in certain breeds. Exocrine pancreatic insufficiency (EPI) frequently causes 
hypocobalaminemia in dogs, with a reported prevalence of up to 82%,28 because the 
majority of intrinsic factor in dogs is believed to be synthesized by pancreatic acinar 
cells, which is therefore deficient in patients with EPI.29 Long-standing and severe ileal 
disease can lead to damage or decreased expression of cobalamin receptors, reducing 
cobalamin absorption and ultimately leading to cobalamin deficiency.26  
Studies in cats with gastrointestinal disease have shown a prevalence of 
cobalamin deficiency from 17% to 61%.30,31 In dogs with chronic gastrointestinal 
disease, the reported prevalence in three studies appears to be lower at 6%, 19%, and 
31%, respectively.1,25,32  
Cobalamin is an essential co-factor for the methylmalonyl CoA mutase enzyme 
systems.27,33-35 L-methylmalonyl CoA mutase converts L-methylmalonyl CoA to 
succinyl CoA. Because this reaction requires adenosyl-cobalamin, patients with 
cobalamin deficiency at the cellular level have a reduced ability to perform this 
conversion, and the metabolism of methylmalonyl CoA is shifted towards an alternate 
pathway. This pathway is catalyzed by D-methylmalonyl CoA hydrolase and results in 
the production of methylmalonic acid (MMA).36 Because production of MMA occurs 
when cellular stores of adenosyl-cobalamin are inadequate, serum MMA concentrations 
may be a useful marker for cobalamin deficiency on a cellular level.34,36,37  
Thus, measurement of the serum MMA concentration may add diagnostic value 
in some canine patients with chronic enteropathies, since serum cobalamin 
concentrations do not always reflect the cellular cobalamin status.37,38 In fact, cellular 
cobalamin status may be more important than serum cobalamin concentrations because 
cobalamin-dependent biochemical reactions take place intracellularly. One previous 
study had shown that cats with hypocobalaminemia had significantly increased serum 
MMA concentrations when compared to healthy cats.33  
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In humans, serum creatinine and MMA concentrations have been shown to 
correlate because excretion of MMA occurs primarily through the kidneys. Thus, renal 
insufficiency may increase serum MMA concentrations unrelated to cobalamin 
deficiency.39-41 This has not yet been investigated in dogs, but increased serum MMA 
concentrations in patients with renal insufficiency may need to be interpreted cautiously. 
While the serum cobalamin concentration is often measured in dogs with chronic 
small intestinal disease, the relationship between serum cobalamin and MMA 
concentrations in dogs has not been reported. The proportion of dogs with 
hypocobalaminemia that have concurrent cobalamin deficiency on a cellular level is 
unknown. Furthermore, it is not known what proportion of dogs with normal serum 
cobalamin concentrations may have evidence of cobalamin deficiency on a cellular 
level.  
Finally, a recent study has suggested that hypocobalaminemia was a risk factor 
for negative outcome in dogs with chronic enteropathies, and may indicate refractoriness 
to treatment.1 However, serum MMA concentrations as an indicator of cobalamin 
deficiency on a cellular level have not previously been investigated in dogs with chronic 
enteropathies. Therefore the number of dogs with evidence of cobalamin deficiency may 
be higher than previously assumed since laboratory assessment was based on serum 
cobalamin concentrations. 
N-Methylhistamine as a marker of intestinal inflammation and mucosal 
mast cell degranulation - Mast cells are increasingly recognized as an important 
sentinel cell type for reactivity of the innate and adaptive immune system.10 They 
express a variety of TLRs and thus can recognize a variety of ligands, including 
microbial proteins.11 They also possess the ability to present antigen,10 making them a 
potentially significant part of the intestinal immune system. Mast cells release a variety 
of inflammatory mediators, including histamine, tryptase, TNF-α, TGF-ß, and a number 
of pro- and anti-inflammatory cytokines.42 Therefore, they can influence intestinal 
function and also participate in acute as well as chronic inflammatory conditions of the 
intestinal tract.43  
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In humans, mast cells can be found throughout all layers of the intestinal wall of 
healthy individuals.43 Furthermore, studies indicate that mast cell density in the human 
colon decreases from the cecal region towards the rectum.44 In healthy dogs, the density 
of mast cells appears to increase from villus tip to crypt while no significant difference 
was found between different regions of the intestinal tract.44   
Increased numbers of mucosal mast cells have been observed in a variety of 
studies investigating human patients with IBD.42,43,45-47 High numbers of mast cells are 
considered suggestive of active disease and inflammation.42 Several studies have shown 
that most of these mast cells are not intact but rather degranulated.43 This indicates that 
participation in the inflammatory process has taken place and further suggests that mast 
cells play a role in the pathophysiology of IBD.43 This assumption is supported by the 
fact that an increased release of histamine in the intestinal mucosa as well as into the 
intestinal lumen has been documented at sites with an increased mast cell density.43 
Because histamine mediates pro-inflammatory effects on other immune cells as well as 
nerve and smooth muscle cells, it may also contribute to some of the clinical signs 
observed in patients with IBD.43 
Histamine is a biogenic amine and a well-documented inflammatory mediator. It 
is primarily stored in mast cells, and to a much lesser extent in basophils, 
enterochromaffin cells, and platelets.48 Histamine has been proposed as a marker of mast 
cell degranulation.42 However, after release from mast cells, histamine is rapidly 
metabolized by either of two pathways, which may interfere with its measurement.   
The first pathway yields imidazole acetic acid via the diamine oxidase enzyme 
system. The second pathway leads to production of N-methylhistamine (NMH) via the 
histamine N-methyltransferase (HNMT) enzyme system.49 In humans, endogenously 
produced histamine is preferentially metabolized through the N-methyltransferase 
pathway.43 Therefore, it has been suggested to use the stable metabolite NMH as a 
marker for mast cell degranulation and gastrointestinal inflammation in people. 
Increased urinary NMH concentrations have been documented in human patients 
with active Crohn’s disease and ulcerative colitis.43,50,51 One study showed that urinary 
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concentrations of NMH correlate with endoscopic severity indices,43 while another 
documented a correlation with disease activity.50 Furthermore, urinary NMH 
concentrations have been shown to correlate with serum CRP concentrations.51 The 
correlation between urinary NMH concentrations and clinical disease activity suggests 
that mast cells become activated only during flare-ups, but do not release histamine at 
other times.50 Thus, the measurement of NMH in urine may provide a useful tool for 
monitoring of disease activity in dogs with chronic enteropathies.  
Several studies in dogs with chronic enteropathies have described the distribution 
of mucosal mast cells in the intestinal tract.52-54 One study reported a reduced number of 
lamina propria mast cells in dogs with idiopathic IBD when tissue was stained with 
toluidine blue.52 Another study found increased numbers of mast cells throughout the 
stomach and small intestine in dogs with idiopathic IBD. However, in this study, mast 
cells were detected using immunohistochemistry (IHC) staining for tryptase.53 A third 
study used both metachromatic and IHC staining procedures and demonstrated 
decreased mast cells using both staining procedures in dogs with lymphoplasmacytic 
enteritis.54   
The different staining methods for mast cells may be important. Metachromatic 
stains work properly only on intact mast cells, whereas degranulated mast cells may not 
be visible. Immunohistochemical stains for mast cell enzymes such as tryptase or 
chymase, however, appear to function even in degranulated mast cells because residues 
of these enzymes are still present within the cell.54 The majority of mast cells detected in 
affected tissues of human patients with IBD were degranulated; therefore, the same 
might occur in canine IBD patients. Depending on the staining method, mast cells may 
not have been detected.  
Aside from differences between metachromatic or IHC staining, intestinal 
mucosal mast cells have been reported to be sensitive to formalin fixation.55 Thus, length 
of fixation and type and concentration of fixative used may have had an impact on the 
outcome of these studies. Furthermore, different stages of inflammation in the dogs 
studied may also have influenced the findings (i.e., some dogs may have had more 
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pronounced mast cell degranulation compared to others). It remains to be determined 
whether dogs with IBD have an overabundance of mucosal mast cells as has been 
reported in human IBD patients.   
An assay for measurement of NMH in canine urine and fecal samples has 
recently been described.56 Fecal NMH concentrations were shown to be increased in 
Norwegian Lundehunds with gastrointestinal disease when compared to healthy control 
dogs.57 Mucosal mast cell staining was not performed in these dogs, and direct 
correlations with fecal NMH concentrations could not be evaluated. However, 
Norwegian Lundehunds have gastrointestinal inflammation, which is usually 
characterized by lymphoplasmacytic infiltration and is generally accompanied by 
intestinal lymphangiectasia.58 Therefore, these dogs may have had high mucosal mast 
cell counts causing an increased histamine release. Furthermore, increased fecal NMH 
concentrations have been detected in some Soft Coated Wheaten Terriers with 
gastrointestinal disease.59 Increased mast cell degranulation has been implicated as a 
potential contributing factor in the development of PLE and PLN in Soft Coated 
Wheaten Terriers.60    
Because the etiology of canine FRD is unknown, it is possible that FRD 
comprises chronic enteropathies with different etiologies, such as true food allergies 
(i.e., reaction mediated by the immune system), dietary intolerance (i.e., reaction not 
mediated by the immune system), and others that are not caused by dietary factors per 
se, but respond to special foods.5 IgE-mediated degranulation of mast cells can cause 
severe clinical signs, because mast cells generally degranulate more rapidly when 
triggered by IgE and antigens than when triggered by other factors.11 Thus, highly 
increased NMH concentrations in fecal or urine samples may be expected in dogs with 
food allergies or hypersensitivities. Food hypersensitivities have been documented in 
Soft Coated Wheaten Terriers,61 and increases in fecal NMH concentrations that have 
previously been observed may also be attributed to such an etiology.  
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1.4 HYPOTHESES AND OBJECTIVES   
The hypotheses for this study are that:  
1. Cobalamin deficiency on a cellular level occurs commonly in dogs with 
chronic enteropathies, and serum methylmalonic acid can serve as a marker of cellular 
cobalamin deficiency. 
2. Fecal and urinary N-methylhistamine concentrations reflect the degree of 
intestinal mucosal mast cell degranulation in dogs with chronic enteropathies.  
The objectives to prove or disprove the aforementioned hypotheses are:  
1. To measure methylmalonic acid concentrations in serum samples from dogs 
with varying serum cobalamin concentrations in order to determine the relationship 
between serum cobalamin and methylmalonic acid concentrations in dogs.  
2. To determine the prevalence of cobalamin deficiency on a cellular level in 
dogs with chronic enteropathies by measuring serum methylmalonic acid concentrations, 
and to correlate these with the serum cobalamin concentrations in these dogs. 
3. To measure N-methylhistamine concentrations in fecal and urine samples from 
dogs with chronic enteropathies and compare these to N-methylhistamine concentrations 
previously measured in healthy control dogs.  
4. To correlate fecal and urinary N-methylhistamine concentrations with the 
clinical activity score (CCECAI) to determine its utility as a marker of active disease and 
clinical activity.  
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2. ASSOCIATION BETWEEN SERUM COBALAMIN AND 
METHYLMALONIC ACID CONCENTRATIONS IN DOGS* 
 
2.1 INTRODUCTION 
Cobalamin (Vitamin B12) undergoes a complex mechanism of absorption, 
involving the pancreas and the distal small intestine.26,27 The two most common causes 
of hypocobalaminemia in dogs are exocrine pancreatic insufficiency (EPI) and severe, 
long-standing ileal disease. While EPI may cause hypocobalaminemia primarily through 
a lack of pancreatic intrinsic factor,29 ileal disease can lead to a decrease in cobalamin 
receptors, and thus reduced absorption of cobalamin.26   
Cobalamin is an essential co-factor for the methylmalonyl CoA mutase 
system.27,33-35 L-methylmalonyl CoA mutase converts L-methylmalonyl CoA to succinyl 
CoA (Figure 2.1). Because this reaction requires adenosyl-cobalamin, patients with 
cellular cobalamin deficiency have a reduced ability to perform this conversion, and the 
metabolism of methylmalonyl CoA is shifted towards an alternate pathway. This 
pathway is catalyzed by D-methylmalonyl CoA hydrolase and results in production of 
methylmalonic acid (MMA).36   
Because production of MMA occurs when cellular stores of adenosyl-cobalamin 
are inadequate, serum MMA concentrations may be a useful marker of cobalamin 
deficiency on a cellular level.34,36,37 This may be of value because the serum cobalamin 
concentration does not always reflect the cellular cobalamin status.37,38 However, 
cellular cobalamin concentrations may be more important than serum cobalamin 
concentrations, because cobalamin dependent biochemical reactions take place 
intracellularly.  
 
 
 
                                                 
*Reprinted with permission from “Association between serum cobalamin and methylmalonic 
acid concentrations in dogs” by Berghoff N, Suchodolski JS, Steiner JM, 2012. Vet J,  
191, 306–311, Copyright 2012 by Elsevier Ltd. 
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Figure 2.1 – Pathway of MMA formation. Propionyl CoA is converted to D-methylmalonyl CoA, which 
can subsequently enter two different pathways. Depicted on the left side, the racemate L-methylmalonyl 
CoA undergoes transformation to succinyl CoA. This reaction is dependent on adenosyl-cobalamin. Thus, 
during states of cobalamin deficiency, this pathway cannot be fully utilized. Instead, the reaction 
illustrated on the right side is favored. This alternative pathway irreversibly converts D-methylmalonyl 
CoA into MMA without the need for cobalamin.  
 
 
 
 
In humans, serum creatinine and MMA concentrations have been shown to 
correlate, because excretion of MMA occurs primarily through the kidneys. Thus, renal 
insufficiency may increase serum MMA concentrations unrelated to cobalamin 
deficiency.39-41 This has not yet been investigated in dogs, but increased serum MMA 
concentrations in patients with renal insufficiency may need to be interpreted with 
caution. 
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While the serum cobalamin concentration is often measured in dogs with chronic 
small intestinal disease, the relationship between serum cobalamin and MMA 
concentrations in dogs has not been reported, and the portion of hypocobalaminemic 
dogs with concurrent cellular cobalamin deficiency is unknown. Furthermore, the 
number of dogs with normal serum cobalamin concentrations but cellular cobalamin 
deficiency is unknown.  
We hypothesized that increased serum MMA concentrations will be present in 
dogs with hypocobalaminemia. Therefore, the aims of this study were: (1) to determine a 
reference interval for MMA concentrations in canine serum, and (2) to evaluate the 
association between serum MMA and cobalamin concentrations in dogs.  
 
 
2.2 MATERIALS AND METHODS  
Samples for determination of the MMA reference interval - Blood samples 
were collected from 43 healthy, client owned dogs. Owners were required to fill out a 
questionnaire to help exclude presence of underlying diseases. A brief physical 
examination was performed by a veterinarian and all dogs appeared healthy. Blood was 
obtained by jugular venipuncture, placed into blood collection tubes without additive 
(Monoject, TYCO Healthcare Group LP), allowed to clot at room temperature, and 
centrifuged at 1,500 x g. Serum was decanted from the clot and stored at -80 °C until 
further use. The Clinical Research Review Committee at the College of Veterinary 
Medicine and Biomedical Sciences, Texas A&M University approved the protocol for 
use of client-owned dogs enrolled in this part of the study (CRRC#: 08-30).  
Samples for evaluating the association between serum cobalamin and MMA 
concentrations - Leftover canine serum samples from submissions to the 
Gastrointestinal Laboratory were collected over a period of 4 months (June – September 
2008). To be included in this study, a sample had to be submitted for a cobalamin assay, 
and a serum volume sufficient to perform MMA analysis had to be available. Sample 
stores were searched for subsequent accessions that fulfilled these criteria, until a 
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sufficient number of samples were collected over a wide range of cobalamin 
concentrations. No exclusions were made based on underlying disease or breed, because 
these were deemed irrelevant for the purpose of this study.  
A total of 555 serum samples were identified, all of which constituted residual 
samples that would otherwise have been discarded. Samples were stored at -20°C from 
the time the cobalamin assay was performed until serum MMA analysis. Internal 
laboratory data show that serum MMA is stable for at least one year when frozen (data 
not shown). Thus, no loss of analyte over the 4-month study period could be expected. 
For statistical analysis, dogs were divided into groups 1 to 10 according to their serum 
cobalamin concentration (Table 2.1).  
Serum cobalamin assay - Serum cobalamin concentrations were determined 
using a competitive binding chemiluminescence assay.a Our laboratory’s reference 
interval for this assay was 251-908 ng/L. The lower and upper detection limits of the 
assay were 150 and 1,000 ng/L, respectively.  
Serum creatinine assay - Serum creatinine concentrations were measured in all 
samples with sufficient sample volume (n = 542), using an automated clinical chemistry 
analyzerb with an enzymatic assay method.c The reference interval for serum creatinine 
was 0.5-1.4 mg/dL. Samples were measured throughout nine assay runs. The intra-assay 
CV% was 0.79%, and the inter-assay CV% was 1.11%. 
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Table 2.1 – Serum MMA concentrations in dogs with varying cobalamin concentrations. Dogs were grouped based on their serum cobalamin 
concentrations. The table shows the median, minimum, and maximum serum MMA concentrations (nmol/L) in each of the 10 groups. Results are shown 
for all 555 samples evaluated, as well as for those 488 dogs that had a serum creatinine concentration below the upper limit of the reference range (≤1.4 
mg/dL). The far right column shows the percentages (and 95% confidence intervals (CI) of the percentages) of dogs with serum MMA concentrations 
above the reference interval in each group (of all 555 dogs).  
 
 
MMA (nmol/L) % Dogs with 
serum MMA above 
the reference 
interval   
All dogs Dogs with creatinine ≤1.4 mg/dL 
Group Cobalamin (ng/L) n Median Min Max n Median Min Max % (95% CI) 
1 <150 72 1,328.0 492.0 24,764.6 60 1,289.0 492.0 24,764.6 63%  (51-73%) 
2 151-250 81 1,033.0 469.1 3,002.6 69 1,038.0 469.1 2,739.8 31%  (21-41%) 
3 251-350 52 759.5 378.9 4,063.6 46 786.0 378.9 4,063.6 19%  (9-30%) 
4 351-450 50 741.9 397.2 2,446.9 40 740.8 397.2 1,955.6 16%  (6-26%) 
5 451-550 60 710.2 405.0 1,396.1 54 692.9 405.0 1,373.6 10%  (2-18%) 
6 551-650 49 690.5 398.6 1,733.3 44 640.3 398.6 1,733.3 14%  (5-24%) 
7 651-750 50 730.3 391.7 1,807.4 48 718.0 391.7 1,515.2  6%  (-1-13%) 
8 751-850 52 820.9 332.0 1,523.1 47 820.1 332.0 1,477.8 10%  (2-18%) 
9 851-950 49 673.6 343.1 1,765.0 47 652.7 343.1 1,765.0 10%  (2-19%) 
10 951-1,000 40 733.0 423.1 1,739.0 33 712.5 423.1 1,739.0 13%  (2-23%) 
  555    488     
 
 
 
 
  
18
Methylmalonic acid assay - Methylmalonic acid was measured using a stable 
isotope dilution gas chromatography/mass spectrometry (GC/MS) method as previously 
described.33 Assay performance was verified using standards prepared with pure MMAd 
in serial dilution from 16,000 to 62.5 nmol/L. The upper limit of the working range for 
the assay was 16,000 nmol/L. Samples with concentrations of 16,000 nmol/L or higher 
were rerun in a dilution to obtain an accurate measurement. MMA was quantified using 
the area under the curve for MMA and the internal standard.e  
Statistical analysis - Data were analyzed using statistical software packages.fg 
Data sets were tested for normal distribution using a D’Agostino & Pearson omnibus 
test. The reference interval for serum MMA was calculated using the central 95th 
percentile. Serum MMA and creatinine concentrations in the 10 groups of dogs were 
compared using a Kruskal-Wallis test with Dunn’s Multiple Comparison test. A χ2-test 
was used to calculate the odds of finding increased serum MMA concentrations in dogs 
with serum cobalamin below and within the reference interval. A χ2-test for trend was 
calculated for the 10 groups of dogs with cobalamin concentrations in ascending order. 
This test takes the sequential order of the groups into account, and was used to determine 
if there was a linear relationship between decreasing serum cobalamin concentrations 
and increasing serum MMA concentrations. The correlation between serum cobalamin 
and MMA concentrations was calculated using Spearman’s rank correlation. The effects 
of age, serum folate, cobalamin, and creatinine concentrations on serum MMA 
concentrations were evaluated using a multiple linear regression model. Statistical 
significance for all tests was set at P < 0.05.  
 
 
2.3 RESULTS  
Reference interval for canine serum MMA concentration - The reference 
interval for canine serum MMA concentration determined in the 43 control dogs was 
414.7-1,192.5 nmol/L (Figure 2.2). The mean serum MMA concentration was 697.8 
nmol/L (95% confidence interval (CI): 625.7-769.9 nmol/L). Mean serum cobalamin 
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concentration was 539 ng/L (95% CI: 492-585 ng/L) and was within the reference 
interval in all control dogs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 – Reference interval for serum MMA concentration. The reference interval based on the central 
95th percentile was calculated as 414.7-1,192.5 nmol/L and is depicted by the two dotted lines. The mean 
MMA concentration in the 43 dogs was 697.8 nmol/L and is represented by the solid black line.  
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Serum creatinine concentrations - Serum creatinine concentrations were 
measured in 542/555 dogs (97.7%). In 13 dogs, serum volumes were insufficient for 
analysis. Serum creatinine concentrations were increased (>1.4 mg/dL) in 54/542 dogs 
(10%). Medians and ranges for serum creatinine concentrations in the 10 groups of dogs 
are shown in Table 2.2.  
 
 
 
 
Table 2.2 – Serum creatinine concentrations in 542 of 555 dogs. Serum creatinine concentrations could not 
be measured in 13 dogs due to insufficient serum volumes.  
 
 
 
 
Creatinine (mg/dL) 
Group Cobalamin 
(ng/L) 
n Median Min  Max  
1 <150 72 0.9 0.3 3.1 
2 151-250 79 1.1 0.3 2.5 
3 251-350 50 1.0 0.3 1.9 
4 351-450 47 1.0 0.5 2.3 
5 451-550 59 0.9 0.1 2.8 
6 551-650 48 0.9 0.3 1.9 
7 651-750 49 0.8 0.3 4.1 
8 751-850 51 0.8 0.3 3.3 
9 851-950 49 0.8 0.1 1.5 
10 951-1,000 38 0.8 0.4 4.6 
  542    
 
 
 
 
 
Association between serum cobalamin and serum MMA concentrations - 
Medians and ranges for serum MMA concentrations in the 555 serum samples are shown 
in Table 2.1 and Figure 2.3. Dogs in groups 1 and 2 (cobalamin < 150 and < 151-250 
ng/L, respectively) had significantly higher serum MMA concentrations than dogs of all 
other groups (P < 0.05), with exception of groups 4 and 8 (cobalamin of 351-450 and 
  
21
751-850 ng/L, respectively), which were not different from group 2. These results did 
not change when dogs with a serum creatinine concentration above the reference interval 
(> 1.4 mg/dL) were excluded from analysis. 
Percentages (and 95% CI) of dogs with MMA concentrations above the upper 
limit of the reference interval in groups 1 through 10 are shown in Table 2.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 – Serum MMA concentrations in 10 groups of dogs (n=555) with cobalamin concentrations 
ranging from <150 ng/L to 1,000 ng/L. The dotted line represents the upper limit of the reference interval 
for canine serum MMA concentrations. Medians in each group are depicted by a solid black line.  
 
 
 
 
Prevalence of cellular cobalamin deficiency as defined by methylmalonic 
acidemia in dogs with a serum cobalamin concentration below the reference interval (< 
251 ng/L) was 46% (95% CI: 38-54%). In dogs with cobalamin concentrations within 
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the reference interval, prevalence of methylmalonic acidemia was 12% (95% CI: 9 - 
15%). The odds ratio for dogs with subnormal cobalamin concentrations to have an 
increased serum MMA concentration (> 1,192.5 nmol/L) was 6.1 (95% CI: 3.9-9.4; P < 
0.0001). The χ2-test for trend, testing for a linear trend between decreasing serum 
cobalamin and increasing serum MMA concentrations, was significant (Chi-square test 
statistic 58.3, P < 0.0001). A weak negative correlation was found between serum 
cobalamin and MMA concentrations (Spearman correlation coefficient ρ: -0.3860; 95% 
CI: -0.4566 to -0.3106; P < 0.0001).  
Multiple regression analysis showed no effect of age, serum folate and serum 
creatinine concentrations on serum MMA concentrations. Serum cobalamin 
concentrations had a significant effect on serum MMA concentrations (P < 0.0001). 
 
 
2.4 DISCUSSION 
This is the first published study investigating the association between serum 
cobalamin and MMA concentrations in dogs. While negative correlation between serum 
cobalamin and MMA concentrations was not strong, the χ2-test for trend showed a linear 
increase in serum MMA concentration with a decreasing serum cobalamin 
concentration. This trend was expected based on the metabolic relationship of cobalamin 
and MMA.  
Sixty-three percent of dogs with undetectable serum cobalamin concentrations (< 
150 ng/L) had increased serum MMA concentrations, indicating cellular cobalamin 
deficiency. If the analysis is expanded to include all dogs with subnormal cobalamin 
concentrations (< 251 ng/L), an increased serum MMA concentration was observed in 
46% of dogs. In cats, this prevalence is reported to be higher at 68%.37 Hence, one may 
have expected a larger percentage of dogs to have increased serum MMA 
concentrations. It is unclear why there is such an interspecies discrepancy, though it is 
possible that there are distinct differences in the way cats and dogs utilize different 
pathways for cobalamin and MMA metabolism. Another potential reason may be the 
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higher prevalence of renal insufficiency in cats when compared to dogs.62 Ruaux et al. 
did not report serum creatinine concentrations; therefore, we cannot rule out that some of 
these cats had renal insufficiency, which may have contributed to increased serum MMA 
concentrations.  
While the prevalence of methylmalonic acidemia in dogs with serum cobalamin 
concentrations within the reference interval was 12%, groups 3 (cobalamin of 251-350 
ng/L) and 4 (cobalamin of 351-450 ng/L) had slightly higher percentages of affected 
dogs with 19% and 16%, respectively. These data imply that some dogs with serum 
cobalamin concentrations in the low normal range may have evidence of cobalamin 
deficiency on a cellular level. It is possible that some of these dogs were supplemented 
with cobalamin prior to analysis. Thus, it is unclear if there was a true deviation between 
serum MMA and cobalamin concentrations, or if some of the normal cobalamin 
concentrations may have been the result of cobalamin supplementation. It is possible that 
hypocobalaminemia was corrected by use of a cobalamin supplement, while it may take 
longer for the tissue to be replenished.  
The lower limit of the serum cobalamin reference interval may not adequately 
reflect the cellular cobalamin status of all dogs. Dogs might have some degree of 
cobalamin deficiency on the cellular level even if serum cobalamin concentrations are 
within the reference interval. This lack of sensitivity of serum cobalamin concentrations 
to detect early cobalamin depletion is suspected to be a reason for discrepancies between 
serum MMA and cobalamin concentrations in humans,34 where this phenomenon is 
termed ‘subtle’ or ‘mild preclinical’ cobalamin deficiency. It is defined as an increased 
concentration of metabolites (e.g., MMA) despite normal or low normal serum 
cobalamin concentrations.34,38 The significance of this condition in dogs is unknown. In 
humans, it is generally not associated with clinical signs, and it is unknown how many 
affected patients progress to clinical cobalamin deficiency.38 Several disorders 
associated with cobalamin deficiency in humans (e.g., neuropathy, anemia) have also 
been reported in patients with subtle cobalamin deficiency, indicating that at least a 
subset of these patients apparently suffer physiological effects of cobalamin deficiency.34 
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Therefore, while progression from the preclinical into the clinical state may be slow or 
even reversible, it may be advisable to treat these patients with cobalamin.41  
In humans, an increased MMA concentration that responds to cobalamin 
supplementation with a significant reduction in serum MMA concentration is considered 
strong evidence, if not proof, of cobalamin deficiency.63 A dose of 1,000 µg of 
cyanocobalamin is considered sufficient to trigger this decrease,39 which may take up to 
5 days to occur.64 A study in cobalamin deficient cats with increased serum MMA 
concentrations showed that MMA concentrations decreased to within normal limits after 
the cats received four weekly doses of 250 µg.65 To determine whether dogs with normal 
cobalamin and increased MMA concentrations are in fact cobalamin deficient, a similar 
cobalamin treatment trial will need to be conducted.  
Limitations of this study include lack of clinical data in the dogs tested. It is 
unknown which clinical signs or diseases were present, or whether any dogs received 
cobalamin supplementation prior to testing. Supplementation could have increased 
serum cobalamin concentrations to within the reference interval, but may not have been 
sufficient to rectify a cellular deficiency. This might explain increased serum MMA 
concentrations in some dogs with normal serum cobalamin concentrations. However, it 
is unlikely that this significantly affected the results for dogs with low serum cobalamin 
concentrations.  
Another limitation is renal insufficiency in some dogs. We measured creatinine 
in 542/555 dogs to evaluate if some of the increased serum MMA concentrations may 
have been due to impaired renal excretion of MMA. Serum MMA and creatinine 
concentrations correlate in humans,38,40 though some argue that this occurs only at 
creatinine concentrations >2.5 mg/dL.39 Even then, increases in serum MMA are only 
moderate (up to 500 nmol/L) with creatinine concentrations as high as 7.9 mg/dL.39 Our 
data showed no association between serum creatinine and MMA concentrations. Thus, 
renal insufficiency was considered unlikely to be contributing to increased serum MMA 
concentrations observed here. 
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Other than cobalamin deficiency and renal insufficiency, there are few known 
causes of methylmalonic acidemia, all of which have only been reported in humans. 
Among these are dehydration, small intestinal bacterial overgrowth (SIBO), and 
inherited defects of the enzyme systems involved in metabolism of cobalamin and 
MMA.27,41,63,66 It cannot be excluded that some dogs included in this study were affected 
by one of these conditions. Dehydration may cause increased serum concentrations of 
both creatinine and MMA, while the effect on serum cobalamin concentration is 
unknown. Theoretically, SIBO may increase serum MMA concentrations if there is an 
overabundance of bacteria producing propionic acid, a precursor of D-methylmalonyl-
CoA.66 An excess of propionic acid could cause increased formation of MMA, and we 
cannot rule out that this may have occurred in some of the dogs. Additionally, SIBO may 
cause cobalamin deficiency because certain bacterial species utilize cobalamin present in 
the intestinal lumen and make it unavailable for absorption by the host.67 Thus, SIBO 
may have a two-fold effect on serum MMA concentrations. 
Little is known about inherited defects of enzymes involved in MMA metabolism 
in dogs. Those disorders that have been described are related to defects in cobalamin 
absorption and are generally accompanied by severe hypocobalaminemia.68-70 Thus, they 
would not explain increased serum MMA concentrations in the presence of normal 
serum cobalamin concentrations.   
A defect in transcobalamin II could potentially cause increased serum MMA 
concentrations despite normal serum cobalamin concentrations, because transcobalamin 
II is the transport protein for cobalamin uptake by the cells.27,34 If delivery into the cells 
is hindered, cellular cobalamin deficiency may result, while serum cobalamin 
concentrations would remain within normal limits. In humans, measurement of 
holotranscobalamin, the biologically active fraction of cobalamin that is bound to 
transcobalamin, has been proposed instead of measuring serum cobalamin 
concentrations.71 Unfortunately, an assay for use in dogs is currently unavailable.   
Conclusions - A large number of dogs with hypocobalaminemia as well as some 
dogs with normal serum cobalamin concentrations have metabolic evidence of cellular 
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cobalamin deficiency as determined by serum MMA concentration. It remains to be 
determined why some dogs have increased serum MMA concentrations despite serum 
cobalamin concentrations within the reference interval, and whether they should be 
supplemented with cobalamin. Supplementation with cobalamin may be justified 
because it has no known side effects and represents an affordable means of treatment. 
An investigation into the effect of cobalamin supplementation in dogs with increased 
serum MMA concentrations and both decreased and normal serum cobalamin 
concentrations is needed to better understand the relationship between serum cobalamin 
and MMA concentrations. 
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3. SERUM COBALAMIN AND METHYLMALONIC ACID 
CONCENTRATIONS IN DOGS WITH CHRONIC  
ENTEROPATHIES* 
 
3.1 INTRODUCTION 
The reported prevalence of hypocobalaminemia in dogs with chronic 
gastrointestinal disease ranges from 6% to 19%.1,32 Cobalamin deficiency may develop 
during chronic and severe small intestinal disease due to damage of mucosal receptors 
for the intrinsic factor (IF)-cobalamin complex, with subsequent reduced cobalamin 
absorption and, once cobalamin stores are depleted, resultant cobalamin deficiency.26  
Cobalamin deficiency in dogs is traditionally assessed by measuring the serum 
cobalamin concentration- a method that provides only a snapshot of the patient's current 
serum cobalamin status but cannot detect cellular cobalamin deficiency. A well-
established method of evaluating the cellular cobalamin status is measurement of serum 
methylmalonic acid (MMA).72,73 Serum concentrations of MMA increase when tissue 
lacks adenosyl-cobalamin, a necessary co-factor for conversion of methylmalonyl-CoA 
to succinyl-CoA. Without cobalamin, the metabolism of methylmalonyl-CoA is shifted 
to an alternate pathway which yields MMA.36 Therefore, increased serum MMA 
concentrations are considered a marker of cellular cobalamin deficiency.27,72,73  
Serum MMA concentrations may also be increased in patients with renal 
insufficiency and correlate with serum creatinine concentrations in humans.40,72 
However, increases in serum MMA concentrations are generally only seen with serum 
creatinine concentrations >2.5 mg/dL, and even then, changes are considered minor in 
magnitude (up to 500 nmol/L).39  
A recent study comparing serum MMA and creatinine concentrations in more 
than 500 canine serum samples did not find a correlation between these two 
                                                 
*Reprinted with permission from “Serum cobalamin and methylmalonic acid concentrations in 
dogs with chronic gastrointestinal disease” by Berghoff N, Parnell NK, Hill S, Suchodolski JS, 
Steiner JS, Am J Vet Res, Accepted for publication, Copyright 2012 by the American Veterinary 
Medical Association. 
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parameters.73 Thus, it appears unlikely that minor variations in serum creatinine 
concentrations would significantly impact the serum MMA concentration. To rule out 
any potential impact of renal insufficiency on the serum MMA concentration, however, 
it may be advisable to evaluate serum creatinine concentrations whenever serum MMA 
concentrations are determined.  
A recent study investigating cobalamin and MMA concentrations in more than 
500 canine serum samples submitted to the Gastrointestinal Laboratory showed that 46% 
of dogs with hypocobalaminemia had evidence of cellular cobalamin deficiency, based 
on an increased serum MMA concentration.73 Furthermore, a number of dogs with low 
normal serum cobalamin concentrations also had increased serum MMA concentrations, 
suggesting cobalamin deficiency on a cellular level despite a normal serum cobalamin 
concentration.73 It was not possible to discriminate between different diseases among 
dogs to classify them into different groups (e.g. chronic gastrointestinal disease vs. other 
diseases, such as gastrointestinal neoplasia or exocrine pancreatic insufficiency).  
Hypocobalaminemia has been found to be a risk factor for negative outcome in 
dogs with chronic gastrointestinal disease,1 suggesting a clinical importance of 
cobalamin in affected dogs. However, the prevalence of cellular cobalamin deficiency in 
dogs with chronic gastrointestinal disease is currently unknown.  
We hypothesize that hypocobalaminemia and cobalamin deficiency on a cellular 
level are common in dogs with chronic gastrointestinal disease. Thus, the aim of this 
study was to determine the proportion of dogs with chronic gastrointestinal disease that 
have hypocobalaminemia and/or methylmalonic acidemia.  
 
 
3.2 MATERIALS AND METHODS 
Patient enrollment and sample collection - In this prospective study, serum 
samples were collected from 69 dogs with chronic gastrointestinal disease. Dogs were 
eligible for enrollment if clinical signs of gastrointestinal disease (e.g., vomiting, 
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diarrhea, weight loss) were present for at least three weeks (at least one clinical sign had 
to be present to be considered for enrollment).  
At the time the sample was obtained from the dog, written owner consent was 
obtained, and the primary veterinarian of the patient assessed the clinical activity index 
(canine chronic enteropathy clinical activity index, CCECAI).1 This scoring index 
evaluates the dog’s attitude/activity, appetite, vomiting, stool consistency, stool 
frequency, weight loss, serum or plasma albumin concentration, presence of ascites or 
peripheral edema, and pruritus. Each parameter is given a score from “0” (normal) to “3” 
(severe change).  
Dogs that had recently been treated with cobalamin were excluded from analysis. 
Furthermore, the canine serum trypsin-like immunoreactivity (cTLI) concentration was 
measured in all patient samples to test dogs for exocrine pancreatic insufficiency (EPI), 
another cause for cobalamin deficiency. Dogs with a subnormal serum cTLI 
concentration (<5.7 µg/L) were excluded. If gastrointestinal histopathology reports were 
available, results were reviewed to exclude dogs with gastrointestinal neoplasia.  
Serum samples were also collected from 43 healthy, client-owned dogs to use as 
control dogs. At the time of blood collection, a brief physical examination was 
performed by a veterinarian, and all dogs appeared healthy. Additionally, owners of the 
dogs were asked to fill out a questionnaire to help exclude the presence of underlying 
diseases. The study was approved by the Clinical Research Review Committee of the 
College of Veterinary Medicine, Texas A&M University (CRRC#09-06 and 08-30). 
Serum creatinine measurement - Routine serum creatinine analyses were 
performed in all samples using an automated chemistry analyzer systemb with an 
enzymatic assay method.c The reference interval for serum creatinine was 0.5–1.4 
mg/dL. The intra-assay CV% was 0.79%, and the inter-assay CV% was 1.11%. 
Serum cobalamin and methylmalonic acid measurement - Serum cobalamin 
concentrations were measured using a competitive binding chemiluminescence assay.a 
Our laboratory’s reference interval for this assay was 251-908 ng/L. The lower and 
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upper detection limits for the cobalamin assay were 150 and 1,000 ng/L, respectively. 
The intra-assay CV% was 8.9%, and the inter-assay CV% was 9.6%.  
Serum MMA concentrations were measured using a stable isotope dilution gas 
chromatography/mass spectrometry (GC/MS) method, as described previously.33,73 
Briefly, MMA was extracted from serum samples using an on-columnh liquid/liquid 
extraction method, followed by silylation with MTBSTFAi for subsequent GC/MS 
analysis.33 GC/MS separation and analysis was performed with a DB-1ms columnj using 
an Agilent 6890N gas chromatograph and 5975C mass selective detectork as described 
elsewhere.33 Assay performance was verified using standards prepared with pure MMAd 
in serial dilution from 16,000 to 63 nmol/L. The reference interval for the MMA assay 
was 415-1,193 nmol/L, and the lower and upper detection limits were 63 and 16,000 
nmol/L, respectively. Serum samples with MMA concentrations higher than 16,000 
nmol/L were rerun at a dilution to allow measurement within the assay’s linear range. 
Diluted sample concentrations were then back-calculated to obtain the actual sample 
concentration. MMA was quantified using the area under the curve for MMA and the 
internal standard (deuterated MMA).e 
Statistical analysis - Data were analyzed using GraphPad Prism 5.00.f All data 
sets were analyzed for normal distribution of data using a D'Agostino & Pearson 
omnibus normality test. The mean (±SD), or the median and ranges of the data sets were 
calculated, as appropriate. Serum cobalamin and MMA concentrations were compared to 
a group of 43 healthy control dogs using a Mann-Whitney U test. A correlation between 
serum cobalamin and MMA concentrations, as well as between both serum parameters 
and the CCECAI in dogs with chronic gastrointestinal disease was evaluated using 
Spearman’s rank correlation. A Spearman’s rank correlation was also calculated for 
serum MMA and serum creatinine concentrations. A possible association between serum 
MMA concentrations and age, as well as duration of clinical signs was evaluated by 
Spearman’s rank correlation as well as a Mann-Whitney U test. Statistical significance 
for all tests was set at p<0.05.  
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3.3 RESULTS 
Signalment of enrolled dogs - A total of 56 of the 69 dogs with gastrointestinal 
disease evaluated were eligible for enrollment. Of the 56 dogs, 29 were female (3 intact, 
26 spayed) and 27 were male (4 intact, 23 castrated). The dogs’ ages ranged from 0.4 to 
13.0 years, with a mean (±SD) of 6.0 ±3.3 years. There was no statistical difference in 
age between female and male dogs (p=0.9743).  
Forty-six dogs were pure bred, with the following frequencies (n): Labrador 
Retriever (4), German Shepherd (3), Boxer (2), Cocker Spaniel (2), English Bulldog (2), 
Golden Retriever (2), Pitbull (2), Pointer (2), Standard Poodle (2), Yorkshire Terrier (2), 
Australian Shepherd (1), Basenji (1), Belgian Malinois (1), Bichon Frise (1), Border 
Collie (1), Boston Terrier (1), Cairn Terrier (1), Chesapeake Bay Retriever (1), Chinese 
Shar Pei (1), English Mastiff (1), French Bulldog (1), Irish Wolfhound (1), Jack Russell 
Terrier (1), Miniature Poodle (1), Miniature Schnauzer (1), Newfoundland (1), 
Pomeranian (1), Rhodesian Ridgeback (1), Soft-Coated Wheaten Terrier (1), Shiba Inu 
(1), Shih Tzu (1), Springer Spaniel (1), and Toy Poodle (1). The remaining 10 dogs were 
of mixed breed, with a mean (±SD) weight of 14.4 ±10.7 kg (range: 2.6-31.5 kg).  
The 43 healthy control dogs consisted of 23 spayed females and 20 males (4 
intact, 16 castrated). The control dogs’ ages ranged from 0.7 to 11.0 years, with a 
median of 3.0 years. There was no statistical difference in age between female and male 
dogs (p= 0.4112). 
Of the control dogs, 29 were purebred, with the following breed frequencies: 
German Shepherd (3), Australian Shepherd (2), Beagle (2), Border Collie (2), Doberman 
Pinscher (2), American Pitbull Terrier (1), American Bulldog (1), Bloodhound (1), Blue 
Heeler (1), Boston Terrier (1), Chesapeake Bay Retriever (1), Welsh Corgi (1), 
Dachshund (1), English Springer Spaniel (1), Foxhound (1), Great Dane (1), Jack 
Russell Terrier (1), Labrador Retriever (1), English Mastiff (1), Neapolitan Mastiff (1), 
Rat Terrier (1), Rottweiler (1), Staffordshire Bull Terrier (1). Fourteen dogs were of 
mixed breed, with a mean (±SD) weight of 24.6 ±7.2 kg (range: 12.0-34.2 kg).  
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Dogs with gastrointestinal disease were significantly older (median [range]: 6.1 
[0.4-13] years) than healthy control dogs (median [range]: 3.0 [0.7-11.0] years; 
p=0.0008). 
Clinical disease activity index - The median CCECAI for the 56 dogs was 6, 
with a range from 1.0-15.0. 
Serum creatinine concentrations - The mean (±SD) serum creatinine 
concentration for the 56 dogs with gastrointestinal disease was 0.9±0.3 mg/dL. Two of 
the 56 dogs had serum creatinine concentrations above the upper limit of the reference 
interval (1.7 and 1.8 mg/dL, respectively). One of these two dogs had an increased 
serum MMA concentration (3,543 nmol/L), and an undetectable serum cobalamin 
concentration (<150 ng/L). There was no correlation between serum MMA and serum 
creatinine concentrations (p=0.5545). 
Serum cobalamin and MMA concentrations - Serum cobalamin 
concentrations in the 56 dogs with chronic gastrointestinal disease (median: 344 ng/L; 
range: 150-1,000 ng/L) were significantly lower than in a group of 43 healthy control 
dogs (median: 515 ng/L, range: 333-835 ng/L; p=0.0011; Figure 3.1). Twenty of the 56 
dogs with gastrointestinal disease (36%) had cobalamin concentrations below the lower 
limit of the reference interval (<251 ng/L), and seven dogs (13%) had undetectable 
serum cobalamin concentrations (<150 ng/L). 
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Figure 3.1 – Serum cobalamin concentrations in 43 healthy control dogs and 56 dogs with chronic 
enteropathies. The lower limit of the reference interval for the serum cobalamin concentration (251 ng/L) 
is depicted by the dotted line. 
 
 
 
 
Median serum MMA concentration in dogs with chronic gastrointestinal disease 
was 741 nmol/L (range: 447-205,399 nmol/L), and serum MMA concentrations in dogs 
with chronic gastrointestinal disease were higher than in the group of 43 healthy dogs 
(median: 649 nmol/L, range: 228-1,253 nmol/L; p=0.0360; Figure 3.2). Five of 56 dogs 
with gastrointestinal disease (9%) had MMA concentrations above the upper limit of the 
reference interval (>1,193 nmol/L). All five of these dogs had undetectable serum 
cobalamin concentrations. Therefore, 25% of hypocobalaminemic dogs had increased 
serum MMA concentrations. 
 
 
 
 
 
  
34
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 – Serum MMA concentrations in 43 healthy control dogs and 56 dogs with chronic 
enteropathies. The upper limit of the reference interval for the serum MMA concentration (1,193 nmol/L) 
is depicted by the dotted line. 
 
 
 
 
When the two dogs with increased serum creatinine concentrations were 
removed from the analysis, serum MMA concentrations between dogs with 
gastrointestinal disease (median: 699 nmol/L, range: 447-205,399 nmol/L) and control 
dogs (median: 649 nmol/L, range: 228-1,253 nmol/L) no longer reached statistical 
significance (p=0.0562).  
There was a moderate, significant negative correlation between serum cobalamin 
and MMA concentrations in dogs with chronic gastrointestinal disease (Spearman r = -
0.4495, p=0.0005). No significant correlations were found between the CCECAI and 
serum cobalamin concentrations or the CCECAI and serum MMA concentrations. 
There was no significant correlation between duration of clinical signs (median 
[range]: 6 [0.75-96] months) and serum MMA concentrations. No significant differences 
were found in duration of clinical signs between dogs that had increased serum MMA 
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concentrations (median [range]: 18 [4-84] months) and dogs with normal MMA 
concentrations (median [range]: 6 [0.75-96] months; p=0.1763).  
Similarly, there was no association between age (median [range]: 6.1 [0.4-13] 
years) and serum MMA concentrations. Age was not significantly different between 
dogs with increased serum MMA concentrations (median [range]: 7.5 [1.8-10] years) 
and dogs with normal serum MMA concentrations (median [range]: 6.0 [0.4-13] years; 
p=0.6874).  
 
 
3.4 DISCUSSION 
The purpose of our study was to investigate the prevalence of 
hypocobalaminemia and cobalamin deficiency on a cellular level (as evidenced by 
increased serum MMA concentrations) in dogs with chronic gastrointestinal disease. To 
our knowledge, this is the first prospective study to determine serum MMA 
concentrations in dogs with chronic gastrointestinal disease.  
The data show a prevalence of 36% for hypocobalaminemia in this group of dogs 
with chronic gastrointestinal disease, which is higher than previously reported for dogs 
with chronic gastrointestinal disease.1,25 Of 20 hypocobalaminemic dogs, 5 dogs (25%) 
also had an increased serum MMA concentration, suggesting cellular cobalamin 
deficiency. This number is lower than reported for dogs with hypocobalaminemia in 
another study,73 and from the data shown in this study it is apparent that the differences 
in serum MMA concentrations between dogs with chronic gastrointestinal disease and 
healthy control dogs is only minor. Significance could no longer be detected once two 
dogs with a slightly increased serum creatinine concentration were removed from 
analysis. We chose to report data with these two dogs included, because data from our 
earlier study, as well as this study failed to indicate a correlation between serum 
creatinine and MMA concentrations in dogs. This is in contrast to humans where such a 
correlation has been reported.40 In the previous study, dogs with a serum creatinine 
concentration as high as 3-4 mg/dL had normal serum MMA concentrations leading us 
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to believe that dogs would probably have to be in severe renal failure before it has a 
potential impact on serum MMA concentrations. Thus, the serum creatinine 
concentrations in the dogs reported here (1.7 and 1.8 mg/dL) probably did not contribute 
to their serum MMA concentrations.   
In the aforementioned earlier study, 46% of dogs with a serum cobalamin 
concentration of less than 251 ng/L had increased serum MMA concentrations.73 The 
prevalence observed in this investigation was only about half as high at 25%. This 
discrepancy is probably due to differences in populations that were sampled for these 
two studies. The earlier study used surplus serum samples that had been submitted to our 
laboratory, and no clinical data were available for dogs included in that study.  
In the current study, dogs with conditions other than chronic gastrointestinal 
disease, such as EPI, or intestinal neoplasia, were excluded from analysis. Exocrine 
pancreatic insufficiency is one of the main causes of cobalamin deficiency in dogs; 
approximately 80% of EPI dogs develop a deficiency.28 Intestinal neoplasia is also more 
likely to cause cobalamin malabsorption, and intestinal lymphoma has been associated 
with cobalamin deficiency in cats.31,74 For example, in this study, all four dogs that had 
been excluded from analysis due to intestinal neoplastic disease had hypocobalaminemia 
and/or methylmalonic acidemia. Therefore, it is conceivable that the described 
differences in the population sample between the two studies are partially responsible for 
the variation in results.  
It is unclear why so many of the dogs with chronic gastrointestinal disease in this 
study had normal serum MMA concentrations despite the presence of low serum 
cobalamin concentrations. It is possible that the disease process in many of these dogs 
was not of sufficient chronicity to deplete cellular stores of cobalamin, which would be 
considered to be a prerequisite to the production of MMA.  
An attempt was made to analyze the association between duration of clinical 
signs and serum MMA concentrations in this study. No significant correlation between 
these two parameters was found. While a trend towards longer duration of clinical signs 
in dogs with high serum MMA concentrations appeared to be present (median of 18 
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months vs. 6 months in dogs with normal serum MMA), it is difficult to evaluate these 
data statistically due to the low number of dogs in the group with high serum MMA 
concentrations (n=5), and no final conclusions should be drawn.  
Half-life of cobalamin in healthy dogs is approximately two months (48-70 
days), which is substantially shorter than in humans, in whom cobalamin half-life is 
approximately one year.31,75 These time frames are only applicable to healthy 
individuals, however. One study found a largely shortened half-life for cobalamin in cats 
with inflammatory bowel disease (5 days) when compared to healthy cats (12.8 days).31 
It is likely that half-life of cobalamin is similarly decreased in dogs with gastrointestinal 
disease, due to reduced absorption while enterohepatic circulation with physiological 
excretion of cobalamin in bile is ongoing.  
Data evaluating the temporal relationship between onset of hypocobalaminemia 
and development of methylmalonic acidemia in dogs are scarce. Studies in dogs with 
selective cobalamin malabsorption due to an inherited defect in the expression of 
proteins in the IF-cobalamin receptor complex (cubam [cubilin and amnionless]) have 
shown that serum MMA concentrations may be increased as early as two weeks after 
onset of hypocobalaminemia.76 However, it is uncertain whether these findings also hold 
true for dogs with cobalamin malabsorption due to chronic gastrointestinal disease. Dogs 
with the inherited defect cannot absorb any cobalamin, whereas this is likely not the case 
in most dogs with gastrointestinal disease in which onset of cobalamin malabsorption 
may be gradual. Thus, further studies investigating the temporal relationship in dogs 
with chronic gastrointestinal disease may be warranted.  
Median clinical activity index (CCECAI) was of moderate severity (median: 6) 
in dogs with gastrointestinal disease, with scores ranging from 1 to 15. There was no 
correlation between CCECAI and serum cobalamin or MMA concentrations, indicating 
that hypocobalaminemia and methylmalonic acidemia are not always associated with 
clinical disease severity. This can be explained by the fact that cobalamin deficiency in 
dogs with chronic gastrointestinal disease is caused by malabsorption of cobalamin due 
to damage to the mucosal receptors for the IF-cobalamin complex in the distal small 
  
38
intestine.26 Therefore, a patient with severe distal small intestinal disease is more likely 
to develop cobalamin deficiency than a patient with disease affecting other sites of the 
intestinal tract. We could not always determine which part of the intestine was primarily 
affected; but, after exclusion of dogs with EPI, it can be assumed that dogs with low 
serum cobalamin concentrations had at least some degree of ileal disease.31  
Consequently, dogs with a high CCECAI yet normal serum cobalamin or MMA 
concentrations may have had more severe disease in other areas of the gastrointestinal 
tract. A potential limitation of our study is that some of the dogs may have received 
cobalamin prior to enrollment into our study, even though we asked treating 
veterinarians about supplementation and dogs were excluded from analysis if cobalamin 
supplementation was indicated as a treatment. In many cases, dogs were enrolled into the 
study through a referral clinic, but the patients had previously been seen by their primary 
care veterinarians. In those dogs, cobalamin may have been supplemented without being 
reported to us. This could have led to some discordance between the serum cobalamin 
concentrations and the clinical scores.  
From the data presented here, we conclude that serum cobalamin deficiency is 
commonly seen in dogs with chronic gastrointestinal disease, but it does not always 
appear to be associated with a cellular cobalamin deficiency. The high prevalence of 
serum cobalamin deficiency in these dogs and the fact that hypocobalaminemia has 
previously been established as a risk factor for negative outcome in dogs with chronic 
gastrointestinal disease1 leads us to believe that serum cobalamin concentrations should 
be measured in all dogs presenting with clinical signs of chronic gastrointestinal disease. 
Supplementation with cobalamin is strongly advised in all patients with a subnormal 
serum cobalamin concentration. It may also be advisable to supplement patients with 
low-normal serum cobalamin concentrations (<350 ng/L) if clinical signs of 
gastrointestinal disease are present. This recommendation is based on evidence that 
shows that cobalamin deficiency itself can cause gastrointestinal abnormalities, such as 
mucosal inflammation and villous atrophy, leading to nutrient malabsorption, including 
cobalamin.26  
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Further studies are warranted to investigate the temporal relationship between the 
onset of serum cobalamin deficiency and cellular cobalamin deficiency in dogs with 
chronic gastrointestinal disease.  
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4. FECAL AND URINARY N-METHYLHISTAMINE CONCENTRATIONS  
IN DOGS WITH CHRONIC ENTEROPATHIES 
 
4.1 INTRODUCTION 
The role of mast cells in canine chronic gastrointestinal diseases is not well 
understood. However, mast cells are increasingly recognized as an important cell type 
for the innate and adaptive immune response.10 They express toll-like receptors, and 
have the ability to present antigens,10 which makes them a potentially significant part of 
the intestinal immune system. Furthermore, mast cells are capable of releasing a variety 
of inflammatory mediators, including histamine, tryptase, TNF-α, TGF-ß, and both pro- 
and anti-inflammatory cytokines.42  
Histamine is primarily stored in mast cells, and only to a much lesser extent in 
other cell types.48 It has been proposed that histamine may be used as a marker of mast 
cell degranulation.42 However, upon release from mast cells during degranulation, 
histamine is rapidly metabolized, making the measurement of histamine unreliable. N-
methylhistamine (NMH) is a stable metabolite of histamine, which is generated from 
histamine by methylation via the histamine N-methyltransferase (HNMT) enzyme 
system.49 N-methylhistamine can readily be measured in both fecal and urine samples, 
and an assay for use in dogs has recently been described and analytically validated.56  
NMH has been suggested as a marker for mast cell degranulation and 
gastrointestinal inflammation in humans with inflammatory bowel disease (IBD) and 
other chronic gastrointestinal diseases.43,50 Increased urinary NMH concentrations have 
been documented in human patients with active Crohn’s disease and ulcerative 
colitis.43,50,51  Urinary concentrations of NMH were shown to correlate with endoscopic 
severity indices,43 clinical disease activity,43,50 and C-reactive protein (CRP) 
concentrations.51 The correlation between urinary NMH concentrations and clinical 
disease activity suggests that mast cells become activated only during flare-ups, but do 
not release significant quantities of histamine at other times.50 Thus, the NMH assay may 
provide a useful tool for monitoring disease activity.  
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Studies in dogs have shown increased fecal NMH concentrations in Norwegian 
Lundehunds and Soft Coated Wheaten Terriers with gastrointestinal disease.57,59 
Interestingly, increased mast cell degranulation has also been implicated as a potential 
contributing factor to the development of protein-losing enteropathy and nephropathy in 
Soft Coated Wheaten Terriers.60  
Minimally invasive or noninvasive markers for gastrointestinal inflammation in 
dogs are currently lacking. For example, serum CRP concentrations have been found to 
be of only moderate clinical utility, and contradicting results have been observed in 
several studies.1,19,24 Measurement of analytes in fecal or urine samples would provide a 
means of non- or minimally invasive evaluation of gastrointestinal inflammation. If 
proven to be clinically useful, such markers could enhance the diagnosis and monitoring 
of clinical patients. 
We hypothesize that fecal and urinary NMH concentrations reflect the degree of 
intestinal mucosal mast cell degranulation in dogs with chronic enteropathies, and could 
therefore serve as a marker of intestinal inflammation in these patients. Therefore, the 
aim of this study was to measure NMH concentrations in fecal and urine samples 
collected from dogs with chronic enteropathies and to compare them to those measured 
in healthy control dogs.  
 
 
4.2 MATERIALS AND METHODS 
Patient eligibility and enrollment - Dogs were eligible for enrollment into this 
prospective study if they had clinical signs of gastrointestinal disease (e.g., vomiting, 
diarrhea, weight loss) for at least three weeks (at least one clinical sign had to be present 
at the time to be considered for enrollment), and gastrointestinal parasitic disease was 
ruled out by fecal examination and/or treatment with anthelmintics. Dogs with known 
concurrent diseases were excluded. Dogs might have been pretreated, as long as all 
treatments were reported to the investigators upon enrollment to allow for subsequent 
classification and, if necessary, exclusion of the patient. Seventy dogs with chronic 
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gastrointestinal disease met initial inclusion criteria. If gastrointestinal histopathology 
reports were available, results were reviewed to exclude dogs with gastrointestinal 
neoplasia.  
Written owner consent was obtained at the time the samples were collected. The 
study was approved by the Clinical Research Review Committee of the College of 
Veterinary Medicine, Texas A&M University (CRRC#09-06). 
Sample collection - At enrollment, the dog’s primary veterinarian assessed the 
clinical activity index for the dog (canine chronic enteropathy clinical activity index, 
CCECAI).1 This scoring index evaluates the dog’s attitude/activity, appetite, vomiting, 
stool consistency, stool frequency, weight loss, serum or plasma albumin concentration, 
presence of ascites or peripheral edema, and pruritus. Each parameter was given a score 
from “0” (normal) to “3” (severe change). To assess clinical severity, the sum of all 
scores was calculated, and interpreted as follows: 0-3=insignificant disease; 4-5=mild 
disease; 6-8=moderate disease; 9-11=severe disease; and ≥12=very severe disease.1 
One serum sample and three consecutive, naturally passed fecal samples were 
collected from each dog. If possible, a urine sample was also obtained by cystocentesis 
(preferred) or by free catch. Fecal samples were frozen immediately after collection. 
Serum and urine samples were stored at 4C until shipment if they were shipped the 
same day, or they were frozen if they were shipped later. All samples were shipped to 
the laboratory overnight on ice. Routine serum analyses were performed immediately 
after arrival, and samples were stored at 4C until analysis was complete. Fecal samples 
were stored at -20C and extracted within one week. Fecal extracts and urine samples 
were stored at -80C until NMH analysis.   
Three consecutive fecal samples were also collected from 49 healthy, client-
owned dogs to use as control dogs.  
Serum routine chemistry analysis - Routine serum chemistry analyses were 
performed using an automated chemistry analyzer system.b Patients with liver enzyme 
activities (ALP, ALT, AST, GGT) of a single enzyme higher than two-fold the 
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laboratory’s reference interval, or with increased activities of more than one liver 
enzyme, were excluded from the study. 
Assessment of gastrointestinal function and disease - Serum cobalamin and 
folate concentrations were measured using competitive binding chemiluminescence 
assays.al Our laboratory’s reference interval for the cobalamin assay was 251-908 ng/L 
and the lower and upper detection limits were 150 and 1,000 ng/L, respectively. The 
reference interval for serum folate concentration was 7.7-24.4 µg/L, and its lower and 
upper detection limits were 1.0 and 24.0 µg/L, respectively.  
The serum canine trypsin-like immunoreactivity (cTLI) concentration was 
measured using a commercially available radioimmunoassaym to test for exocrine 
pancreatic insufficiency (EPI). The reference interval for this assay was 5.7 to 45.2 µg/L. 
Dogs with a subnormal serum cTLI concentration (less than 5.7 µg/L) were excluded 
from the study.  
Serum canine pancreatic lipase immunoreactivity (PLI) was measured as Spec 
cPL®.n The reference interval for this assay was 0-200 µg/L. Spec cPL concentrations 
higher than 400 µg/L were considered consistent with pancreatitis, and patients with 
Spec cPL concentrations >400 µg/L were excluded from the study. Concentrations of 
201-399 µg/L were considered questionable. 
Concentrations of C-reactive protein (CRP) in serum samples were measured 
using a commercially available ELISA assay kit.o Our laboratory’s reference interval for 
the CRP assay was ≤7.6 mg/L. 
Fecal canine alpha1-proteinase inhibitor (1-PI) concentrations were measured in 
all three consecutive fecal samples from each dog using a previously described 
radioimmunoassay (RIA).77 Prior to analysis, a liquid extract of each fecal sample was 
prepared as previously described.78 Briefly, fecal samples were diluted 1:5 in PBS-
NBCS,p followed by vigorous agitation on an automated vortex shaker for 20 min. 
Samples were subsequently centrifuged for 20 min at 2,100 x g and then filtered using a 
serum filter.q The resultant supernatant was again centrifuged for 30 min at 10,000 x g. 
This second supernatant (= final fecal extract) was decanted and aliquots were stored at -
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80C until analysis. For the fecal 1-PI RIA, a further 1:200 dilution of the final fecal 
extract in RIA bufferr was prepared.  
To account for variability among the three fecal samples, both the 3-day mean 
fecal 1-PI concentration and the maximum concentration for the three days (3-day 
maximum) were calculated.79 The reference intervals for the mean and maximum 1-PI 
were 2.2-13.9 μg/g and 2.2-21.0 μg/g, respectively.77  
N-methylhistamine assay - N-methylhistamine was measured in fecal extracts 
and urine samples using stable isotope dilution gas chromatography/mass spectrometry 
(GC/MS), based on a previously reported method.49,56 For fecal NMH analysis, the same 
final fecal extract (1:5 dilution) as described for 1-PI analysis was used.  
To allow for quantification of NMH, a known amount of trideuterated NMH (d3-
NMH, 2.5 µL of a 200 µg/mL solution) was added to 500 µL of liquid fecal extract or 
urine sample as an internal standard. After further addition of 500 µL of borate buffer,s 
samples were vortexed thoroughly and applied to a silica solid-phase extraction column.t 
The columns were washed with two 1 mL aliquots of ultrapure wateru and samples were 
eluted from the column with three 1 mL aliquots of acidified methanol.v Eluates were 
dried under a stream of nitrogen, re-dissolved in 300 µL of 20% methanol in chloroform, 
and applied to a second silica column. The column was briefly washed with a 150 µL 
aliquot of 20% methanol in chloroform, followed by elution of the samples using four 1 
mL volumes of methanol:chloroform:ammonium hydroxide (25:25:1, v/v). After eluates 
were dried under a stream of nitrogen, samples were derivatized for GC/MS analysis by 
acylation with pentafluoropropionic anhydride (PFPA).w To each sample, 200 µl of ethyl 
acetate, 40 µL of pyridine, and 100 µL of PFPA were added. Samples were vortexed 
thoroughly, covered with thermoplastic laboratory film, and incubated at 64C for 40 
min. After derivatization, samples were evaporated once more under a stream of 
nitrogen. During the following partitioning step, 500 µL of Tris buffer and 1.5 mL of 
hexane were added to each sample and vigorously shaken on a vortex mixer for 1 min. 
After separation of the aqueous and hexane layers, the hexane layer was aspirated from 
the sample tube and placed into a clean sample tube. A second 1.5 mL hexane aliquot 
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was added to the Tris-sample tube, the partitioning step was repeated, and the combined 
hexane fractions were evaporated to dryness under a stream of nitrogen. The residue was 
dissolved in 30 µL of ethyl acetate, and transferred to a GC/MS autosampler vial.  
The GC/MS analysis was performed using an Agilent 6890N GC and 5975C 
MSDx with a dimethylpolysiloxane capillary column.j Samples of 1 µL volume were 
automatically injected into the GC inlet at 250C in splitless mode, with an inlet pressure 
of 16.9 psi, and a total inlet flow of 19.6 mL/min. Helium was used as carrier gas at a 
constant column flow rate of 2.0 mL/min (velocity of 51 cm/sec). The initial column 
temperature was held at 50C for 0.50 min, after which a temperature ramp was applied 
with a gradient of 20C/min until 175C was reached. The gradient was increased to 
50C/min up to a final temperature of 300C, which was held for 2.00 min, resulting in a 
total run time of 11.25 min. The MS was operated in selected ion monitoring mode with 
ions at mass-to-charge ratios (m/z) of 417 and 420 for NMH and d3-NMH, respectively 
(dwell time 100 msec). The MS source temperature was 230C, quadrupole temperature 
was 150C, and transfer line temperature was 250C. Assay performance was verified by 
use of standards with NMH concentrations ranging from 0 to 5,000 pg/µL.  
Urinary NMH concentrations were normalized against urine creatinine 
concentrations and expressed in ng/mg creatinine. A urinary NMH concentration of  
>136 ng/mg creatinine was considered abnormal.56 Fecal NMH concentrations were 
back-calculated for the wet weight of the fecal samples and expressed in ng/g feces. 
Similar to the fecal 1-PI assay, both 3-day mean and 3-day maximum concentrations 
were calculated for the fecal NMH assay. The reference intervals for the 3-day mean and 
maximum fecal NMH concentrations were ≤191 ng/g feces, and ≤334 ng/g feces, 
respectively.  
Urine creatinine assay - Urine creatinine concentrations for normalization of 
urinary NMH concentrations were measured in all urine samples using an automated 
chemistry analyzer systemb with an enzymatic assay method.c Urine samples were 
diluted 1:20 in purified water before analysis to ensure sample concentrations within the 
linear range of the assay (<30 mg/dL creatinine).  
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Statistical analysis - Data were analyzed using GraphPad Prism 5.00.f All data 
sets were analyzed for normal distribution of data using a D'Agostino & Pearson 
omnibus normality test. Mean (±SD), or the median and ranges of the data sets were 
calculated, as appropriate. The CCECAI scores, though normally distributed, were 
reported as medians due to the categorical nature of the data. Fecal NMH concentrations 
were compared between dogs with gastrointestinal disease and healthy control dogs 
using a Mann-Whitney U test. Correlations between data sets were calculated using 
Spearman’s rank correlation (rs). Frequency distributions were analyzed using Fisher’s 
exact test. To assess the relationship between fecal and urinary NMH concentrations and 
histological severity, inflammatory infiltrates were grouped as mild or moderate-severe, 
and outcomes were categorized as normal or increased NMH concentrations. This 
analysis was carried out separately for urinary and fecal NMH concentrations, and was 
also separated into analysis of gastric tissue only, duodenal tissue only, or both tissues 
combined. Statistical significance for all tests was set at p<0.05.  
 
 
4.3 RESULTS 
Signalment of enrolled dogs - Forty-seven of the 70 dogs initially evaluated met 
the inclusion criteria and were included in the study. Of these, 24 were female (2 intact, 
22 spayed), and 23 were male (3 intact, 20 castrated). The median age of the 47 dogs 
was 6.0 years, with a range from 0.4 to 12.0 years. There was no significant difference in 
age between females and males (p= 0.755).  
Of the 47 dogs, 37 were purebred. The breeds most commonly seen were the 
German Shepherd (3), Labrador Retriever (3), Chinese Shar Pei (2), Cocker Spaniel (2), 
Golden Retriever (2), Pitbull (2), Pointer (2), and Yorkshire Terrier (2). All other 
purebred dogs were represented by only one member of their breed. Among these were a 
Boxer and a Soft Coated Wheaten Terrier. The remaining 10 dogs were of mixed breed, 
and included two Yorkshire Terrier crossbreeds.  
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The 49 control dogs comprised 22 females (1 intact, 21 spayed) and 27 males (4 
intact, 23 castrated). The median age of the 49 dogs was 3.8 years (range: 0.5 to 17.3 
years). There was no significant difference in age between control dogs and dogs with 
gastrointestinal disease (p=0.106). Of the 49 control dogs, 21 were mixed breed dogs 
and 28 were pure breeds. The most common breeds were Beagle (n=3), Dachshund (2), 
Pug (2), and Yorkshire Terrier (2). All other breeds were represented by a single dog 
each, among these one Boxer and a German Shepherd.  
 Clinical disease activity index and clinical signs - Median CCECAI for the 47 
dogs was 6 (range: 1.0-14.0), which corresponds to moderate disease activity. The most 
frequently observed clinical signs were diarrhea with weight loss (8), followed by 
diarrhea only (7), vomiting with diarrhea (6), and vomiting with diarrhea, weight loss 
and inappetence (6). The remaining dogs had various combinations of the four above 
mentioned clinical signs.  
Serum routine chemistry profile results - Notable abnormalities found on 
routine serum chemistry profiles were hypoproteinemia in 26 dogs (55%), and 
hypoalbuminemia in 14 dogs (30%). Hypocalcemia was noted in 14 dogs (30%), 11 of 
which were hypoalbuminemic and hypoproteinemic, and another three of which only 
were hypoproteinemic. There was a positive correlation between serum calcium and 
albumin concentrations (Spearman rs=0.8182), and calcium and total protein 
concentrations (rs=0.7669; p<0.0001 for both). Hypocholesterolemia was seen in 10 
dogs (21%), and moderate positive correlations were also found between serum 
cholesterol concentrations and serum albumin (rs=0.4666), total protein (rs=0.5095), and 
calcium concentrations (rs=0.5108; p<0.001 for all).  
Assessment of gastrointestinal function and disease - For serum cobalamin 
concentration, only 45 of 47 dogs could be assessed, as two dogs had received 
cobalamin supplements prior to testing. Of these 45 dogs, 16 (34%) were 
hypocobalaminemic (<251 ng/L). Four of 47 dogs (9%) had a low serum folate 
concentration.  
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Five dogs (11%) had a serum Spec cPL® concentration within the equivocal 
range of the assay (201-399 µg/L), with the remainder of the dogs having Spec cPL 
concentrations within the reference interval. 
Serum CRP concentrations were increased in 21/47 dogs (45%; median [range]: 
15.6 mg/L [7.9-112.9]). Median (range) CRP concentration for all 47 dogs was 3.2 mg/L 
(0.1-112.9). There was a significant correlation between serum CRP concentrations and 
the CCECAI scores (rs=0.3382, p=0.020).  
 Fifteen of the 47 dogs (32%) had increased 3-day mean fecal 1-PI 
concentrations, with a median of 7.2 µg/g feces for all 47 dogs (range: 2.2-402.0). 
Similarly, 16/47 dogs (34%) had increased 3-day maximum fecal 1-PI concentrations 
(median [range]: 9.2 µg/g feces [2.2-432.1]). All dogs with an increased 3-day mean also 
had increased 3-day maximum 1-PI concentrations. A moderate negative correlation 
was found between the fecal 1-PI concentration, and serum albumin concentration (3-
day mean: rs=-0.3501, p=0.016; 3-day max: rs=-0.3342, p=0.022), as well as total protein 
concentration (3-day mean: rs=-0.4549, p=0.001; 3-day max: rs=-0.4603, p=0.001). 
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Fecal and urinary N-methylhistamine concentrations - Of 47 dogs, 9 (19%) 
had increased 3-day mean fecal NMH concentrations (median [range]: 2,465 ng/g [218-
4,690]). Median 3-day mean fecal NMH concentration in all 47 dogs with 
gastrointestinal disease was 96 ng/g (range: 0-4,690), which was significantly higher 
than in control dogs (median [range]: 53 ng/g [9-252]; p=0.026; Figure 4.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 – 3-day mean fecal NMH concentrations in dogs with chronic enteropathies and healthy control 
dogs. 3-day mean fecal NMH concentrations were increased in 9 dogs (19%) with chronic enteropathies 
(median [range] in 9 dogs with increased NMH concentrations: 2,465 ng/g [218-4,690]). Overall medians 
in both groups are depicted by the solid black lines. The dotted line represents the upper limit of the 
reference interval (<191 ng/g feces).  
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The 3-day maximum fecal NMH concentrations were increased in 10/47 dogs 
(21%; median [range]: 2,777 ng/g [343-7,059]), which included the 9 dogs with an 
increased 3-day mean fecal NMH. Correspondingly, the 3-day maximum fecal NMH 
concentration in dogs with gastrointestinal disease (median [range]: 149 ng/g [0-7,059]) 
was significantly higher than in control dogs (median [range]: 83 ng/g [14-666]; 
p=0.018; Figure 4.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 – 3-day maximum fecal NMH concentrations in dogs with chronic enteropathies and healthy 
control dogs. 3-day maximum fecal NMH concentrations were increased in 10 dogs (21%) with chronic 
enteropathies (median [range] in 10 dogs with increased NMH concentrations: 2,777 ng/g [343-7,059]). 
Overall medians in both groups are depicted by the solid black lines. The dotted line represents the upper 
limit of the reference interval (<334 ng/g feces).  
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Urine was available from 41/47 dogs (87%). Eleven of 41 dogs (27%) had 
increased urinary NMH concentrations. Three of these 11 dogs also had increased fecal 
NMH concentrations. Neither 3-day mean nor maximum fecal NMH concentration 
correlated with urinary NMH concentrations (p=0.941 and p=0.609, respectively).  
A weak correlation was found between urinary NMH concentrations and serum 
CRP concentrations (rs=0.3121, p=0.047; Table 4.1). However, no correlations were 
found between fecal NMH concentrations and the serum CRP concentrations, or any of 
the NMH concentrations and CCECAI scores. There was no correlation between fecal or 
urinary NMH concentrations and serum total protein or albumin concentrations, nor 
were dogs with increased NMH concentrations more likely to have low serum protein 
concentrations.  
Data analysis was repeated using only those dogs in which gastrointestinal 
inflammation had been confirmed by histopathology, and from which complete sample 
sets were available (i.e., both fecal and urine samples available; n=23). Overall results 
were similar to those obtained with all 47 dogs included (see Table 4.2 and 4.3). 
However, the correlation between urinary NMH concentrations and serum CRP 
concentration, which was weak when all 47 dogs were included, was stronger when only 
dogs with confirmed gastrointestinal inflammation were included (rs=0.6546, p=0.001; 
Table 4.1). 
Analyses were also repeated after excluding dogs that had been pre-treated with 
either H2-receptor antagonists, glucocorticoids, or both, in order to rule out a potential 
impact of these treatments on the outcome of the analysis. None of the dogs had received 
proton pump inhibitors. Analyses were done on both groupings of dogs, the 47 original 
dogs, and only those 23 dogs for which gastrointestinal inflammation had been 
confirmed histopathologically. Results were calculated after exclusion of dogs that 
received H2-receptor antagonists (resulting in 37 and 18 untreated dogs for all dogs and 
the dogs with histopathology results, respectively), after exclusion of dogs that received 
glucocorticoids (42 and 21 dogs, respectively), as well as after exclusion of all pre-
treated dogs (32 and 16 dogs, respectively; Table 4.1, 4.2 and 4.3). Results showed no 
  
52
large changes in outcome of the t-test comparison to control dogs. The overall 
percentage of dogs with increased fecal NMH concentrations increased after exclusions 
were made. However, the correlation between CRP and urinary NMH concentrations 
remained moderately strong in the histopathology group, even after removal of dogs that 
were treated with steroids or H2 receptor antagonists, whereas the correlation between 
CRP and the CCECAI was no longer statistically significant once treated dogs were 
removed (Table 4.1).  
 
 
 
 
Table 4.1 – Correlations of serum CRP concentrations with the CCECAI and urinary NMH 
concentrations. Correlations between serum CRP concentrations and the CCECAI, as well as urinary 
NMH concentrations in all 47 enrolled dogs, and all dogs not treated with histamine receptor antagonists 
and/or glucocorticoids. The Spearman correlation coefficient (rs), as well as the p-value of the correlation 
are given for each analysis. The analysis was repeated to include only those dogs for which 
gastrointestinal inflammation had been confirmed histopathologically (n=23). 
 
    Correlations  
CRP vs. CCECAI  CRP vs. urinary NMH 
n  Spearman rs  p  Spearman rs  p 
         
All dogs  47 0.3382  0.020 0.3121  0.047 
no HA treatment  37 ‐  ns  ‐  ns 
no GC treatment  42 ‐  ns  0.3352  0.043 
no HA or GC treatment  32 ‐  ns  ‐  ns 
Dogs with histopathology  23 0.4270  0.042 0.6546  0.001 
no HA treatment  18 ‐  ns  0.6164  0.006 
no GC treatment  21 ‐  ns  0.6415  0.002 
no HA or GC treatment  16 ‐  ns  0.5916  0.016 
         
 
HA=histamine receptor antagonist; GC=glucocorticoids; ns=not significant 
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Table 4.2 – Comparison of 3-day mean fecal NMH concentrations. Comparison of 3-day mean fecal NMH concentrations in all 47 enrolled dogs, and of 
all dogs not treated with histamine antagonists and/or glucocorticoids. Percentages of dogs with increased fecal NMH concentrations (with medians and 
ranges) are given for each group. The analysis was repeated to include only those dogs for which gastrointestinal inflammation had been confirmed 
histopathologically (n=23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
HA=histamine receptor antagonist; GC=glucocorticoids         
*p-value of the t-test comparison to healthy control dogs: control dog median (range) for 3-day mean was 53 ng/g (9-252). 
 
 
 
 
3‐day mean fecal NMH concentration [ng/g feces] 
  Dogs with increased NMH 
n  Median (range)  t‐test p*  n  %   Median (range) 
           
All dogs  47 96 (0‐4,690)  0.026  9  19%  2,465 (218‐4,690) 
no HA treatment  37 97 (0‐4,690)  0.006  8  22%  2,665 (218‐4,690) 
no GC treatment  42 98 (0‐4,690)  0.005  8  19%  2,666 (218‐4,690) 
no HA or GC treatment  32 104 (14‐4,690)  0.001  7  22%  2,598 (218‐4,690) 
Dogs with histopathology  23 109 (0‐4,515)  0.015  6  26%  2,665 (1,728‐4,515) 
no HA treatment  18 126 (0‐4,515)  0.008  6  33%  2,665 (1,728‐4,515) 
no GC treatment  21 109 (0‐4,515)  0.010  5  24%  2,598 (1,728‐4,515) 
no HA or GC treatment  16 126 (14‐4,515)  0.004  5  31%  2,598 (1,728‐4,515) 
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Table 4.3 – Comparison of 3-day maximum fecal NMH concentrations. Comparison of the 3-day maximum fecal NMH concentrations in all 47 enrolled 
dogs, and all the dogs not treated with histamine antagonists and/or glucocorticoids. Percentages of dogs with increased fecal NMH concentrations (with 
medians and ranges) are given for each group. The analysis was repeated to include only those dogs for which gastrointestinal inflammation had been 
confirmed histopathologically (n=23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
HA=histamine receptor antagonist; GC=glucocorticoids         
* p-value of the t-test comparison to healthy control dogs: control dog median (range) for 3-day maximum was 83 ng/g (14-666). 
3‐day maximum fecal NMH concentration [ng/g feces] 
  Dogs with increased NMH 
n  Median (range)  t‐test p*  n  %  Median (range) 
           
All dogs  47 149 (0‐7,059)  0.018  10  21%  2,777 (343‐7,059) 
no HA treatment  37 160 (0‐7,059)  0.005  9  24%  2,907 (343‐7,059) 
no GC treatment  42 167 (0‐7,059)  0.003  9  21%  2,733 (343‐7,059) 
no HA or GC treatment  32 178 (27‐7,059)  <0.001  8  24%  3,037 (343‐7,059) 
Dogs with histopathology  23 177 (0‐7,059)  0.017  7  30%  2,907 (343‐7,059) 
no HA treatment  18 172 (0‐7,059)  0.017  7  39%  2,907 (343‐7,059) 
no GC treatment  21 177 (0‐7,059)  0.017  6  29%  3,037 (343‐7,059) 
no HA or GC treatment  16 172 (27‐7,059)  0.010  6  38%  3,037 (343‐7,059) 
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Frequency distribution analysis revealed a significant association between 
urinary NMH concentrations and severity of mucosal inflammation in the duodenum 
(p=0.008, Figure 4.3).  
In contrast, no significant association of fecal NMH concentration and mucosal 
inflammatory severity was found either for the stomach or the duodenum.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 – Comparison of urinary NMH concentrations with mild versus moderate-severe 
gastrointestinal inflammation in the duodenum. This figure shows the comparison of urinary NMH 
concentrations with the degree of inflammation in the duodenal mucosa (p=0.008). Dogs with urinary 
NMH concentrations below the upper limit of the control range (≤136 ng/mg creatinine) are shown in 
white, dogs with increased urinary NMH concentrations are shown in dark grey.  
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4.4 DISCUSSION 
To our knowledge, this is the first prospective study to investigate fecal and 
urinary NMH concentrations in a large group of dogs with chronic gastrointestinal 
disease. Preliminary data in Norwegian Lundehunds and Soft Coated Wheaten Terriers 
have been reported,57,59 but our goal was to investigate a larger group of dogs 
representative of a typical clinical patient set, instead of restricting our patient group to 
dogs of breeds known to have a higher prevalence of chronic enteropathies.  
The aim of this study was to determine if fecal or urinary NMH concentrations 
are increased in dogs with chronic gastrointestinal disease, and whether measuring NMH 
in fecal or urinary specimens could serve as a useful marker of inflammation.   
Results demonstrated that fecal and urinary NMH concentrations were increased 
in 21% (feces) to 27% (urine) of dogs with chronic gastrointestinal disease. This 
increase is indicative of mast cell degranulation, and suggests involvement of mast cells 
in the disease process. However, unlike in humans with IBD, in whom urinary NMH 
concentrations correlate with the clinical disease activity index and serum CRP 
concentration, no correlation could be observed for the 47 dogs in this study for either 
urinary or fecal NMH concentrations in regards to the CCECAI.  
There was a weak correlation between urinary NMH concentration and CRP 
concentration when all 47 dogs were analyzed. In human patients, the serum CRP 
concentration represents an important measure for evaluation of disease activity in 
chronic gastrointestinal inflammation because of its short half-life.80 Half-life of CRP in 
dogs is assumed to be equally short,81 and its use as a marker of disease activity and 
severity in dogs with chronic gastrointestinal disease has been evaluated in several 
studies, with varying results.1,19,24 In our study, the clinical activity index correlated with 
serum CRP concentrations, but not to the NMH concentrations. This suggests that NMH 
may not be a good indicator of disease activity in dogs with chronic gastrointestinal 
disease, as measured by the CCECAI. 
Interestingly, when analysis was reduced to 23 dogs with histologically 
confirmed gastrointestinal inflammation, the correlation between urinary NMH and 
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serum CRP concentrations was significantly stronger than in the group including all 47 
dogs. The serum CRP concentration in these 23 dogs was higher (median [range]: 8.0 
mg/L [0.1-112.9]) than in the group of all 47 dogs (median [range]: 3.2 mg/L [0.1-
112.9]). It is possible that the 23 dogs had more severe gastrointestinal inflammation, 
representing a different disease group than the remaining dogs, which may have led to a 
stronger association between the parameters investigated. 
Comparison of the grade of histological inflammation (mild vs. moderate-severe) 
with urinary or fecal NMH concentrations revealed a significant association between 
urinary NMH concentrations and the grade of inflammation in the duodenal, but not the 
gastric mucosa. This suggests that urinary NMH concentrations may be more accurate 
for detection of intestinal than gastric inflammation. Fecal NMH concentrations did not 
have any association with mucosal inflammation. This observation is in agreement with 
studies in humans with IBD, in whom urinary NMH concentrations are a more accurate 
indicator of disease severity than fecal NMH concentrations.  
One limitation of our study is a lack of follow-up data; therefore it was not 
always possible to designate dogs to specific subgroups, such as food-, antibiotic-, or 
steroid-responsive disease. It is conceivable that better characterization of subgroups 
could have identified an association between increases in NMH concentrations and a 
specific disease group. Follow-up data was available for a small number of dogs that did 
not allow for statistical analysis. Based on those dogs, no association between NMH 
concentrations and any treatment response could be detected. However, follow-up data 
on a larger number of dogs may provide a different outcome.   
Another limitation is that some of the dogs had been pre-treated with 
glucocorticoids and/or antihistamines, and the effect this may have had on fecal or 
urinary NMH concentrations is unknown. We therefore modified our analysis to exclude 
dogs that had received glucocorticoids and/or antihistamine treatment (e.g. H2 blockers), 
and repeated all statistical tests. No profound changes in statistical outcome were found, 
leading us to believe that these treatments did not have a significant impact on our 
results.  
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All dogs in this study were enrolled either with newly presenting disease, or with 
ongoing clinical signs despite prior treatment (i.e., treatment failures), suggesting that if 
they had received pre-treatment, the therapeutic attempts were not successful in treating 
the underlying disease process. Regardless, a potential influence of treatments on mast 
cell mediated inflammation cannot be excluded.   
For future studies, treatment trials with different classes of antihistamines (H1 
blockers vs. H2 blockers), as well as mast cell stabilizers (e.g. cromolyn sodium, 
ketotifen) in dogs with increased NMH concentrations may be warranted. Preliminary 
data in Soft Coated Wheaten Terriers with PLE have shown some therapeutic success in 
dogs resistant to traditional therapeutic intervention when treated with cromolyn 
sodium.82 Increased fecal NMH concentrations have been found in Soft Coated Wheaten 
Terriers with gastrointestinal disease, and this finding is intriguing. 
To our knowledge, this was the first study to simultaneously evaluate fecal and 
urinary N-methylhistamine concentrations in any species. Studies in humans have 
evaluated either urinary43,50 or fecal NMH concentrations,83 but no comparison has been 
made between the two sample types at the same time. In our study, fecal and urinary 
NMH concentrations did not correlate with each other, and only three of 11 dogs with 
increased urinary NMH concentrations had simultaneously increased fecal NMH 
concentrations. Due to lack of comparable studies in human medicine, it is unknown 
whether this result may be due to our specific group of dogs, or whether fecal and 
urinary NMH concentrations in general do not tend to correlate with each other.  
Studies in humans, however, have shown that urinary NMH concentrations tend 
to be a better indicator of clinical disease activity in IBD patients than fecal NMH 
concentrations.43 There may be several reasons for this observation.  
First, histamine can be metabolized either via diamine oxidase to imidazole 
acetic acid, or, as described here, via histamine N-methyltransferase (HNMT) to NMH. 
Diamine oxidase is released from villous epithelial cells via intracellular vesicles, and 
then acts as an extracellular enzyme.84 Within the gastrointestinal tract, it presumably 
converts primarily food-derived, intraluminal histamine.85 Histamine N-
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methyltransferase on the other hand, is a cytosolic enzyme with intracellular action,85 
and it has been shown that the vast majority of endogenously released histamine is 
metabolized via the HNMT pathway.43,86 It is possible that histamine released from mast 
cells that are located closer to the mucosal surface may be partially subjected to 
metabolism by diamine oxidase, because a portion of it may enter the intestinal lumen 
before it has been converted to NMH. This scenario could produce some discordance in 
fecal versus urinary NMH concentrations. 
Second, distribution of mast cells within intestinal layers could lead to a similar 
disagreement. Histamine released by mast cells in the lamina propria or submucosa is 
converted to NMH, and may subsequently enter the blood or lymphatic system to be 
excreted in the urine, whereas NMH originating from mast cells closer to the mucosal 
surface may be more likely to be released into the intestinal lumen. If more mast cells 
are located towards the lamina propria and submucosa, versus the mucosa, an increase in 
NMH concentrations may more likely be seen in the urine, rather than the feces. An 
investigation of the distribution of mast cells in canine gastrointestinal biopsies in 
regards to fecal and urinary NMH concentrations is ongoing, and may help answer some 
of these questions.  
Lastly, it is not known to what extent an uptake of NMH along the 
gastrointestinal tract with subsequent urinary excretion may occur, and how this may be 
affected by disease location within the gastrointestinal tract.  
In summary, lack of correlation between NMH concentrations and the clinical 
activity index suggests that NMH may not be a good marker for clinical disease activity 
in dogs. However, these data show that some dogs with chronic gastrointestinal disease 
have increased fecal and/or urinary NMH concentrations, which indicates increased mast 
cell activity and involvement of mast cells in the disease process. Therefore, urinary 
and/or fecal NMH concentrations may possibly function as an independent marker of 
inflammation. Due to the detected association to serum CRP concentrations and severity 
of mucosal inflammation, urinary NMH concentrations may be a more suitable marker 
of intestinal inflammation than fecal NMH concentrations, which would be in agreement 
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with studies in human patients. Future studies are warranted to further characterize the 
role of mast cell mediated inflammation in dogs with chronic gastrointestinal disease. 
Also, evaluation of the potential benefit of alternative treatment approaches targeting 
mast cell stabilization and/or inhibition of mast cell mediator action may be facilitated if 
NMH can be used as a marker of mast cell degranulation.  
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5. SUMMARY AND CONCLUSION 
 
5.1 SUMMARY 
  Diagnosis and management of chronic enteropathies in dogs often remains a 
challenge. Non-invasive laboratory tests are lacking, and a diagnosis is generally made 
based on exclusion of other possible disease processes.  
  Regardless of the type of enteropathy, assessment of clinical disease activity 
can be useful at initial diagnosis and each time the patient is re-evaluated, to ensure 
adequate therapy is initiated and appropriately modified. Clinical activity indices for use 
in dogs with chronic enteropathies have been proposed,1,24 but few laboratory tests have 
aided in the assessment of these patients. Serum or plasma albumin concentration is an 
objective parameter that is factored into the CCECAI, increasing the score if the albumin 
concentration is below the lower limit of the reference interval.1 Also, while the serum 
cobalamin concentration is not taken into account for calculation of the clinical activity 
index, decreased serum concentrations of cobalamin have been associated with a 
negative outcome.1 Correlation between serum CRP concentration and clinical activity 
has been reported in dogs with at least moderate disease,24 but other studies have not 
reproduced this finding. Thus, identification of other laboratory parameters that may be 
useful as markers of active disease, or that could aid in assessment of patients with 
chronic enteropathies is desirable.  
  This study was designed to characterize two separate aspects of canine chronic 
enteropathies. One was to investigate the prevalence of cobalamin deficiency on a 
cellular level in dogs with chronic gastrointestinal disease by measurement of serum 
MMA concentration. The purpose of this investigation was to determine if dogs with 
evidence of cobalamin deficiency could be identified that would have gone undetected if 
only the serum cobalamin concentration had been measured. Based on the fact that 
hypocobalaminemia is a risk factor for negative outcome in dogs with chronic 
enteropathies, identification of dogs with cobalamin deficiency on a cellular level may 
be of clinical importance. The second objective of the study was to investigate the utility 
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of measuring fecal and urinary NMH concentrations as novel markers of intestinal 
inflammation and clinical activity in dogs with chronic enteropathies.  
 First, in order to determine the relationship between serum MMA and cobalamin 
concentrations in dogs, MMA concentrations were measured in a large sample set of 555 
canine serum samples with serum cobalamin concentrations ranging from undetectable 
(<150) to 1,000 ng/L. To allow for interpretation of the serum MMA concentrations, a 
reference interval for canine serum MMA concentrations was established based on 43 
healthy control dogs, and was determined as 415-1,193 nmol/L.  
 Results showed that 46% of hypocobalaminemic dogs (<251 ng/L) had increased 
serum MMA concentrations. Not unexpectedly, this proportion was even higher (63%) 
in dogs with undetectable serum cobalamin concentrations. Increased serum MMA 
concentrations (i.e., 16%-19% increase) were also seen in dogs with serum cobalamin 
concentrations as high as 350-450 ng/L, indicating that some dogs with normal serum 
cobalamin concentrations also have evidence of cellular cobalamin deficiency. This 
finding was interesting, as it suggested cellular cobalamin deficiency without concurrent 
hypocobalaminemia in a subset of the dogs evaluated. One factor known to increase 
serum MMA concentrations in the face of normal serum cobalamin concentrations is 
renal insufficiency. In humans, serum creatinine concentrations have been found to 
correlate with serum MMA concentrations. In this study, serum creatinine 
concentrations were measured in all serum samples for which sufficient serum was 
available (542/555), and concentrations were increased (>1.4 mg/dL) in 10% of samples. 
However, no influence of serum creatinine concentration on serum MMA concentration 
could be detected by regression analysis. Thus, it is unlikely that renal insufficiency 
contributed to the increased serum MMA concentrations observed in these dogs.  
 Further studies are needed to investigate whether dogs with increased serum 
MMA concentrations and normal serum cobalamin concentrations would benefit from 
cobalamin supplementation. For example, a trial could be carried out by supplementing 
these dogs with cobalamin. If cobalamin supplementation results in a significant 
decrease in serum MMA concentration, it is highly likely that the dog had cellular 
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cobalamin deficiency. If that were the case, a recommendation to treat dogs that have an 
increased serum MMA concentration in the face of normocobalaminemia with 
cobalamin supplementation may be warranted. Supplementation with cobalamin may be 
justified regardless, because it has no known side effects and represents an affordable 
means of treatment.  
 To investigate the prevalence of cobalamin deficiency on a cellular level in dogs 
with chronic enteropathies, serum samples were collected from 56 dogs, and cobalamin 
and MMA concentrations were measured in all samples. Hypocobalaminemia was found 
in 36% of these dogs, whereas methylmalonic acidemia was detected in only 9% of these 
dogs, all of which had undetectable serum cobalamin concentrations. Thus, 75% of 
hypocobalaminemic dogs had serum MMA concentrations within the reference interval, 
and only 25% had increased MMA concentrations. 
 This finding is in contrast to the almost 50% of hypocobalaminemic dogs with 
methylmalonic acidemia reported in the previous study.73 A difference between the two 
study populations is likely responsible for this discrepancy. Our previous study utilized 
surplus serum samples, and no clinical data was available for the dogs. For the second 
study, only dogs with chronic enteropathies were enrolled, and those with 
gastrointestinal neoplasia and EPI were excluded, which likely produced a very different 
sample set in regards to etiologies, which may not be comparable to the previous study. 
However, it is still unclear why so many dogs with chronic gastrointestinal disease and 
hypocobalaminemia had normal serum MMA concentrations. One possible explanation 
is that the disease process in dogs with normal MMA concentrations may not have been 
of sufficient chronicity to cause cellular depletion of cobalamin and thus production of 
MMA. Therefore, the association between duration of clinical signs and serum MMA 
concentrations was explored. While there appeared to be a trend towards longer duration 
of clinical signs in dogs with increased serum MMA concentrations, no significant 
correlation was detected. Data on the temporal relationship between the onset of 
hypocobalaminemia and methylmalonic acidemia are scarce. Studies in dogs with 
selective cobalamin malabsorption due to a receptor defect indicate that serum 
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methylmalonic acid concentrations increase within as little as two weeks after onset of 
cobalamin deficiency. However, it is uncertain whether these findings are relevant for 
dogs with cobalamin malabsorption due to gastrointestinal disease, and studies 
investigating this temporal relationship in dogs with chronic gastrointestinal disease may 
be warranted. 
 Based on these data, it can be concluded that serum cobalamin deficiency is 
common in dogs with chronic gastrointestinal disease, but that it is not always associated 
with cellular cobalamin deficiency. The high prevalence of cobalamin deficiency in the 
dogs studied here suggests that serum cobalamin concentrations should be measured in 
all dogs with clinical signs of chronic gastrointestinal disease, to ensure that cobalamin 
supplementation can be initiated if necessary. This investigation did not identify any 
dogs with cellular cobalamin deficiency that did not also have concurrent 
hypocobalaminemia.  
 For the second part of the study, fecal and urinary NMH concentrations were 
measured in dogs with chronic enteropathies to investigate whether NMH could serve as 
a useful marker of inflammation and may aid in assessment of clinical activity in dogs 
with chronic enteropathies. Increased NMH concentrations in urine or fecal samples are 
indicative of mast cell degranulation, and therefore involvement of mast cells in the 
gastrointestinal disease process. Results showed increased fecal NMH concentrations in 
21% of dogs, and increased urinary NMH concentrations in 27% of the dogs enrolled.  
 While urinary NMH concentrations in human patients with IBD correlate to the 
clinical activity index, no correlation was observed for the dogs in this study for either 
urinary or fecal NMH concentrations. A correlation between urinary NMH 
concentrations and serum CRP concentrations was found, which mirrors studies in 
human patients, in whom CRP and urinary NMH concentrations also correlate. This 
correlation became significantly stronger when the sample size was reduced to only 
include those dogs with histopathologically confirmed gastrointestinal inflammation. It 
is not unexpected to find this result, because availability of histopathological 
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confirmation of inflammation yields an improved case definition and a more closely 
defined group of patients.  
Additionally, analysis of frequency distributions for the histological grade of 
inflammation (mild vs. moderate-severe) compared to urinary and fecal NMH 
concentrations showed a significant association between urinary NMH concentrations 
and the grade of inflammation in the duodenum. This suggests that urinary NMH 
concentrations may be more accurate for detection of intestinal, rather than gastric 
inflammation. Further studies are needed to determine the degree of mast cell 
involvement in gastric and duodenal inflammation in dogs. Fecal NMH concentrations 
were not associated with mucosal inflammation. This finding is in agreement with 
studies in human patients with IBD, in whom urinary NMH concentrations have been 
found to be a more accurate indicator of disease severity than fecal NMH concentrations.  
Because this was the first investigation to simultaneously evaluate fecal and 
urinary N-methylhistamine concentrations in any species, it is unknown whether the lack 
of correlation between urinary and fecal NMH concentrations was due to our specific 
group of dogs, or whether they do not tend to correlate with each other in general. 
However, based on the studies in humans with IBD mentioned above, it is likely that 
urinary NMH concentrations are a better indicator of clinical disease activity and 
inflammation than fecal NMH concentrations, and this may be similar in dogs. 
Modification of our analysis to exclude dogs that had been pre-treated with 
glucocorticoids and/or antihistamines prior to enrollment revealed no major changes in 
statistical outcomes for the parameters investigated. Treatments administered were likely 
given for varying lengths of time and an exact analysis of the effect of either H2 
blockers or glucocorticoids would be difficult. It is possible that more NMH-positive 
dogs may have been identified if all dogs had been untreated, because a potential 
influence of treatments on mast cell mediated inflammation cannot be excluded; further 
studies are necessary to investigate the effect of antihistamine or glucocorticoid 
treatment on fecal and urinary NMH concentrations in dogs.  
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5.2 CONCLUSIONS 
In conclusion, these data demonstrate that hypocobalaminemia is common in 
dogs with chronic gastrointestinal disease, but is not always associated with cobalamin 
deficiency on a cellular level. In this investigation of dogs with chronic enteropathies, no 
dogs were identified with cellular cobalamin deficiency that did not also have concurrent 
hypocobalaminemia.  
Furthermore, some dogs with chronic gastrointestinal disease have increased 
fecal and/or urinary NMH concentrations, suggesting increased mast cell degranulation 
and involvement of mast cells in the disease process. No correlation of fecal or urinary 
NMH concentration to the clinical activity index was found, suggesting that NMH may 
not be a good marker for clinical disease activity as determined by CCECAI. However, 
urinary NMH concentrations may have clinical utility based on their correlation to serum 
CRP concentrations and an association with the severity of intestinal mucosal 
inflammation. Fecal NMH concentrations did not correlate with serum CRP 
concentrations or severity of inflammation. Future studies are warranted to further 
characterize the role of mast cell mediated inflammation in dogs with chronic 
gastrointestinal disease. Measurement of urinary and fecal NMH concentrations may be 
a useful adjunct marker in these studies.    
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ENDNOTES 
 
a Immulite 2000 Vitamin B12, Siemens Healthcare Diagnostics Inc., Deerfield, Ill. 
b Sirrus Clinical Chemistry Analyzer, Stanbio Laboratory, Boerne, Tex. 
c Direct Creatinine LiquiColor Test, Stanbio Laboratory, Boerne, Tex. 
d Methylmalonic acid, Sigma-Aldrich, St. Louis, Mo. 
e Methyl-d3-malonic acid, CDN Isotopes, Pointe-Claire, QC, Canada 
f GraphPad Software, San Diego, CA 
g JMP 8.0.2, SAS Institute, Inc. s 
h Chem Elut Cartridges, 1 mL, unbuffered, Agilent Technologies, Santa Clara, Calif. 
i MTBSTFA, #TS-48920, Thermo Fisher Scientific, Waltham, Mass. 
j DB-1ms #122-0132, 30 m length, 0.25 mm diameter, 0.25 µm film thickness, Agilent 
Technologies, Santa Clara, Calif. 
k Agilent Technologies, Santa Clara, Calif. 
l Immulite 2000 Folic Acid, Siemens Healthcare Diagnostics Inc., Deerfield, Ill. 
m Double Antibody Canine Trypsin-Like Immunoreactivity (TLI), Siemens Medical 
Solutions Diagnostics, Los Angeles, Calif. 
n IDEXX Laboratories, Westbrook, Maine 
o PHASE™ EIA Canine CRP Assay, Tridelta Development, Ltd., Maynooth, County 
Kildare, Ireland 
p PBS-NBCS: phosphate-buffered saline (BupH™, Thermo Fisher Scientific, Rockford, 
Ill.) with 5% (v/v) newborn calf serum (Sigma-Aldrich, St. Louis, Mo.), 1% (v/v) Triton 
X-100 (Surfact-Amps® X-100, Thermo Fisher Scientific, Rockford, Ill.), and 0.25 mM 
thimerosal (Sigma-Aldrich, St. Louis, Mo.) 
q Fisherbrand IB Model Serum Filters, Fisher Scientific Inc., Pittsburgh, Pa. 
r RIA buffer (pH 7.5): 0.05 M sodium phosphate, 0.02% (w/v) sodium azide, 0.5% (w/v) 
BSA 
s Sodium tetraborate decahydrate 10 mM, pH 9.0, Sigma-Aldrich, St. Louis, Mo. 
t SepPak®Vac Silica, 1cc, 100 mg, Waters Corporation, Milford, Mass. 
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u Burdick & Jackson® water, Honeywell Burdick &Jackson, Muskegon, Mich. 
v 0.1 M HCl in methanol 
w Pentafluoropropionic anhydride, Sigma-Aldrich, St. Louis, Mo. 
x Agilent 6890N gas chromatograph and 5975C mass selective detector, Agilent 
Technologies, Santa Clara, Calif. 
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